Skip Navigation
Johns Hopkins Bloomberg School of Public HealthCAAT

Thomas Hartung Publications

For the latest news and updates, please visit our CAATwalk Newsletter archives. And sign up to get it delivered straight to your inbox. 

Scientific Publications

542 Papers (in Medline-listed journals with impact factor 2013, total 2013.7

h-factor: 83 (Google Scholar), over 20,400 (ResearchGate) / 25.700 (Google Scholar) citations 


Top 10 journals

  • Nature (IF 38.6): 3 articles
  • Circulation (IF 15.2): 1 article
  • J. Exp. Med (IF 13.2): 2 articles
  • Angew. Chem. (IF 13.7): 1 article
  • Advanced Drug Delivery Reviews (12.9): 1 article
  • Hepatology (IF 12.0): 1 article
  • Journal of Allergy and Clinical Immunology (IF 11.5): 1 article
  • J. Hepatology (IF 9.9): 1 article
  • PNAS & Trends Biotechnology (IF 9.7): 4 & 1 articles
  • Blood (IF 9.1): 4 articles
  • Nature protocols (IF 8.0): 1 article

10 most frequent journals

  • ALTEX (IF 4.1): 137 articles
  • ATLA (IF 1.4): 33 articles
  • J. Immunol. (IF 5.5): 19 articles
  • Infect. Immun. (IF 4.1): 11 articles
  • Human Exp. Toxicol. (IF 1.5): 10 articles
  • Toxicol. In Vitro (IF 2.7): 9 articles
  • J. Biol. Chem. (IF 4.7) 9 articles
  • J. Immunol. Meth. (IF 2.2): 8 articles
  • J. Inf. Dis. (IF 5.9) / Eur. J. Immunol. (IF 5.0) / Immunobiol. (IF 2.8): 6 articles each
  • J. Endotox. Res. (now Innate Immunity) (IF 2.7): 5 articles

Thomas Hartung Publications (updated November 2018)

1. Abreu CM, Gama L, Krasemann S, Chesnut M, Odwin-Dacosta S, Hogberg H, Hartungand Pamies D. Microglia increase inflammatory responses in iPSC-dervied human BrainSpheres. Frontiers Microbiology 2018, in press. (IF 4.3)

2.  Alves VM, Capuzzi SJ, Braga RC, Borba JVB, Silva AC, Luechtefeld T, HartungT, Andrade CH, Muratova EN and Tropsha A. A perspective and a new integrated computational strategy for skin sensitization assessment.Sustainable Chemistry & Engineering 2018, 6:2845-2859. (IF 6.0)

3. Beilmann M, Boonen H, Czich A, Dear G, Hewitt P, Mow T, Newham P, Oinonen T, Pognan F, Roth A, Valentin J-P, van Goethem F, Weaver R J, Birk B, Boyer B, Caloni F, Chen AE, Corvi R, Cronin MTD, Daneshian M, Ewart LC, FitzGerald RE, Hamilton GA, HartungT, Kangas JD, Kramer NI, Leist M, Marx U, Polak S, Rovida C, Testai E, van de Water B, Vulto P, and Steger-Hartmann T. Optimizing drug discovery by Investigative Toxicology: Current and future trends – Report of CAAT-ITL Forum Think Tank. Submitted.

4. Chesnut M, Yamada T, Adams T, Knight D, Kleinstreuer N, Kass G, Luechtefeld T, Hartung T and Maertens A. Regulatory Acceptance of Read-Across: Report from an International Satellite Meeting at the 56th Annual Meeting of the Society of Toxicology. ALTEX 2018, 35:413-419. (IF 4.1)

5. Delp J, Gutbier S, Cerff M, Zasada C, Niedenführ S, Zhao L, Smirnova L, HartungT, Borlinghaus H, Schreiber F, Bergemann J, Gätgens J, Beyss M, Azzouzi S, Waldmann T, Kempa S, Nöh K, and Leist M. Stage-specific metabolic features of differentiating neurons: implications for toxicant sensitivity. Toxicology Applied Pharmacology, 354:64-80. doi: 10.1016/j.taap.2017.12.013. (IF 4.0)

6. Goldberg A, Leist M and HartungT. The Center for Alternatives to Animal Testing (CAAT) in the USA and Europe. In: Balls M, Combes M and Worth A. The History of Alternative Test Methods in Toxicology (chapter 2.11). Elsevier, in press.

7. Harris G, Eschment M, Perez Orozco S, McCaffery JM, Severin D, Kleensang A, Freeman D, Pamies D, Delp J, Leist M, Maertens A, Hogberg H, Kirkwood A, Hartung T and Smirnova L. Toxicity, recovery and resilience in a 3D dopaminergic in vitro model exposed to Rotenone. Arch Toxicol, in press (IF 5.1).

8. Hartung T. Making big sense from big data. Frontiers in Big Data, 2018, Frontiers in Big Data 1:5. doi: 10.3389/fdata.2018.00005 

9.  HartungT. Rebooting the Generally Recognized as Safe (GRAS) approach for food additive safety in the US. ALTEX 2018, 35:3-25. (IF 4.1)

10. Hartung T.Perspectives on in vitroto in vivoextrapolations. Journal of Applied In Vitro Toxicology, in press. 

11. HartungT. Research and testing without animals – where are we now and where are we heading? in: Herrman K and Jayne K (Eds), Animal experimentation: Working towards a paradigm change. Brill, Leiden, The Netherlands, in press.

12. Kleensang A, Maertens A and HartungT. From big data to predictive analysis from in vitro systems. In: Atala A and Murphy S. Regenerative Medicine Technology: On-a-chip Applications for Disease Modeling, Drug Discovery and Personalized Medicine. CRC Press, in press.

13. Krewski D, Andersen M, Tyshenko MG, Krishnan K, HartungT, Boekelheide K, Wambaugh JF, Jones D, Whelan M, Thomas R, Yauk C, Barton-Maclaren T and Cote I. Toxicity Testing in the 21st Century: Progress in the past decade and future perspectives. Submitted.

14. Luechtefeld T, Wong H-L, Kim J, Lin N, Begum A, Tsaioun K, Prawira A, Dai D, Chooback N, Nappi L, Samawi H, Lavoie J-M, Spreafico A, Hansen AR, Sahebjam S, Siu LL, Ivy SP, HartungT, Renouf D, and Paller CF. Sysrev - semi automated systematic review to enhance biomedical information management. JAMIA. Submitted.

15. Luechtefeld T, Rowlands C and HartungT. Big-data and machine learning to revamp computational toxicology and its use in risk assessment. Toxicological Research 2018, 7:732-744, doi:10.1039/C8TX00051D.(IF 4.3)

16.  Luechtefeld T, Marsh D, Rowlands C and HartungT. Machine learning of toxicological big data enables read-across structure activity relationships (RASAR) outperforming animal test reproducibility. Toxicological Sciences, 2018, 165:198-212. doi: 10.1093/toxsci/kfy152. (IF 4.3)

17.  Maertens A and HartungT. Green toxicology – know early about and avoid toxic product liabilities. Toxicol. Sci. 2018, 161:285–289. DOI: 10.1093/toxsci/kfx243.(IF 4.3)

18.  Maertens A, Tran V, Kleensang A and HartungT. Weighted gene correlation network analysis (WGCNA) reveals novel transcription factors associated with Bisphenol A dose-response. Frontiers in Genetics, section Bioinformatics and Computational Biology 2018, 9:508. doi: 10.3389/fgene.2018.00508. (IF 4.2)

19.  Meigs L, Smirnova L, Rovida C, Leist M and HartungT. Animal testing and its alternatives – the most important omics is economics. ALTEX 2018, 35:275-305. doi: 10.14573/altex.1807041(IF 4.1)

20.  Pamies D, Block K, Lau P, Gribaldo L, Pardo C, Barreras P, Smirnova L, Wiersma D, Zhao L, Harris G, HartungT and Hogberg HT. Rotenone exerts developmental neurotoxicity in a Human Brain Spheroid model. Toxicol Appl Phramacol 2018, in print. (IF 4.0)

21.  Pamies D, Wiersma D, Katt MC, Zhao L, Harris G, Smirnova L, Odwin-Dacosta S, Cassia R, Searson PC, HartungT, and Hogberg HT. A toxicant-induced dopaminergic neuronal loss approach in a 3D human brain microphysiological system to study Parkinson’s disease. Under revision.

22.  Pamies D, Bal-Price A, Chesne C, Coecke S, Dinnyes A, Eskes C, Grillari, Gstraunthaler G, HartungT, Jennings, P., Leist M, Martin U, Passier R, Schwamborn JC, Stacey GN, Ellinger-Ziegelbauer H and Daneshian M. Advanced Good Cell Culture Practice for human primary, stem cell-derived and organoid models as well as microphysiological systems. ALTEX, 2018, 35:353-378. doi:10.14573/altex.1710081.(IF 4.1)

23.  Plummer S, Wallace S, Ball G, Lloyd R, Schiapparelli P, Quiñones-Hinojosa A, HartungT and Pamies D. A Human iPSC-derived 3D platform to study brain cancer drug development and personalized medicine. Submitted. 

24.  Salem H, Dorsey R, Carmany D and HartungT. In vivo, in vitro and stem cell technologies to predict human pharmacology and toxicology. In: Atala A and Murphy S. Regenerative Medicine Technology: On-a-chip Applications for Disease Modeling, Drug Discovery and Personalized Medicine. CRC Press, in press.

25.  Smirnova L, Kleinstreuer N, Corvi R, Levchenko A, Fitzpatrick SC and HartungT. 3S – Systematic, systemic, and systems biology and toxicology. ALTEX 2018, 35:139-162.  doi:10.14573/altex.1804051 (IF 4.1)

26.  Smirnova, L., and Hartung, T. Human 3D In Vitro Models for Developmental Neurotoxicity. In Slikker W, Paule MG and Wang C (eds.). Handbook of Developmental Neurotoxicology, 2ndedition, Chapter 14, 2018, 163–172, Elsevier.

27.  Stephens ML, Gül Akgün Ölmez S, Hoffmann S, de Vries R, HartungT, Maertens A, Witters H, Lalu M and Tsaioun K. Application of systematic review methods to the assessment of test method performance: lessons learned from a pilot study of the zebrafish embryotoxicity test. Submitted.

28.  Volz T, Kaesler S, Draing C, HartungT, Röcken M, Skabytska Y and Biedermann T. Induction of IL-10-balanced immune profiles following exposure to LTA from Staphylococcus epidermidis. Experimental Dermatology, 27:318-326. (2.5)


29.  Aschner M, Ceccatelli S, Daneshian M, Fritsche E, Hasiwa N, HartungT, Hogberg HT, Leist M, Li A, Mundy WR, Padilla S, Piersma AH, Bal-Price A, Seiler A, Westerink R, Zimmer B and Lein P. Selection of reference compounds for characterization and development of alternative methods for developmental neurotoxicity (DNT) testing. ALTEX 2017, 34:49-74. doi: 10.14573/altex.1604201 (IF 4.1)

30.  Bowman CE, Rodriguez S, Alpergin ESS, Acoba MG, Zhao L, HartungT, Claypool SM, Watkins PA and Wolfgang MJ. The mammalian malonyl-CoA synthetase ACSF3 is required for mitochondrial protein malonylation and metabolic efficiency. Cell Chem. Biol. 2017, 24:673-684.e4. doi: 10.1016/j.chembiol.2017.04.009. (IF 4.5).

31.  Busquet F and HartungT. The need for strategic development of safety sciences. ALTEX 2017, 34:3-21. (IF 4.1)

32.  Corvi R and HartungT. Alternative approaches for carcinogenicity and reproductive toxicity. In: Balls M, Combes M and Worth A. The History of Alternative Test Methods in Toxicology (chapter 3.7). Elsevier, in press.

33.  Crawford SE, HartungT, Hollert H, Mathes B, van Ravenzwaay B, Steger-Hartman T, Studer C and Krug HF. Green toxicology: A strategy for sustainable chemical and material development. Environmental Sciences Europe 2017, 29:16. doi: 10.1186/s12302-017-0115-z. Available at:

34.  Elgogary A, Xu Q, Poore B, Alt J, Zimmermann SC, Zhao L, Fu J, Chen B, Xia S, Liu Y, Neisser M, Nguyen C, Lee R, Park JK, Reyes J, HartungT, Rojas C, Rais R, Tsukamoto T, Semenza GL, Hanes J, Slusher BS and Le A. Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer. Proc. Natl. Acad. Sci. U S A 2017, 113:E5328-5336. DOI: 10.1073/pnas.1611406113 (IF 9.4)

35.  Escher BI, Hackermüller J, Polte T, Scholz S, Aigner A, Altenburger R, Böhme A, Bopp SK, Brack W, Busch W, Chadeau-Hyam M, Covaci A, Eisenträger A, Galligan J, Garcia-Reyero N, HartungT, Hein M, Herberth G, Jahnke A, Kleinjans J, Kluever N, Krauss M, Lamoree M, Lehmann I, Luckenbach T, Miller GW, Mueller A, Phillips DH, Rappaport SM, Reemtsma T, Rolle-Kampczyk U, Schüürmann G, Schwikowski B, Tan Y-M, Trump S, Walter-Rohde S and Wambaugh JF. From the exposome to mechanistic understanding of chemical-induced adverse effects. Environment International 2017, 99:97–106 Available online. 5.6)

36.  Eskes C, Boström A-C, Bowe G, Coecke S, HartungT, Hendriks G, Pamies D, Piton A and Rovida C. Good Cell Culture Practices & In Vitro Toxicology. Toxicology In Vitro 2017, pii: S0887-2333(17) 30107-8. doi: 10.1016/j.tiv.2017.04.022. (IF 2.7)

37.  Fowle JJR III, Curren RD, HartungT, Proctor C and Wilcox N. Twenty-First Century In VitroToxicology Testing Methods and the Assessment of e-Cigarettes. Applied in Vitro Toxicology 2017, 3: 3–9. 

38.  Harris G, Hogberg H, HartungT and Smirnova L. 3D differentiation of LUHMES cell line to study recovery and delayed neurotoxic effects. Current Protocols in Toxicology 2017, 73, 11.23.1–11.23.28. doi: 10.1002/cptx.29. (IF 1.3).

39.  HartungT. Thresholds of Toxicological Concern – setting a threshold for testing where there is little concern. ALTEX 2017, 34:331-351. doi: 10.14573/altex.1707011. (IF 4.1)

40.  HartungT. Utility of the Adverse Outcome Pathway concept in drug development. Expert Opinion In Drug Metabolism and Toxicology 2017, 13:1-3. (IF 2.8)

41.  Hartung T, Hogberg HT, Leist M, Pamies D and Smirnova L. Advanced cell techniques to study developmental neurobiology and toxicology. In: Slikker W and Wang C. Neural Cell Biology. Chapter 18. 2017, Taylor & Francis Group, LLC, 187-217.

42.  HartungT. Alternativen zu Tierversuchen. In: Greim H. and Deml E. Toxikologie: Eine Einführung für Naturwissenschaftler und Mediziner. 2ndedition, Wiley, in press.

43.  Hartung, T. Alternatives to animal testing. In: Greim H and Snyder R. Toxicology and Risk Assessment: A Comprehensive Introduction, 2ndedition, Wiley, in press

44.  HartungT. Evolution of toxicological science: the need for change. International Journal of Risk Assessment and Management 2017, 20:21-45. 

45.  HartungT and Rovida C. Prospettive della ricerca scientifica attraverso metodi alternative alla sperimentazione animale. In: Ferroni MV and Campanaro C. (Ed). Metodi alternative alla sperimentazione animale. G. Giappichelli Editore, Torino, 17-23.

46.  HartungT, Kavlock R and Sturla S. Systems Toxicology II: a special issue. Chemical Research in Toxicology 2017, 30:869–869.(IF 3.5)

47.  Hartung T. Opinion versus evidence for the need to move away from animal testing. ALTEX 2017, 34:193-200. (IF 4.1)

48.  Hartung T. Food for Thought ... the first ten years. ALTEX 2017, 34:187-192. (IF 4.1)

49.  Hartung T, FitzGerald R, Jennings P, Miriams G, Peitsch M, Rostami-Hodjegan A, Shah I, Wilks M, and Sturla S. Systems toxicology - Real world applications and opportunities. Chemical Research in Toxicology 2017, 30:870–882. DOI: 10.1021/acs.chemrestox.7b00003. (IF 3.5)

50.  HartungT. Introduction and overview. In: Comprehensive Medicinal Chemistry III: ADME and Toxicology: A Comprehensive Overview of the Current Status and Application of Predictive ADMET. Elsevier, in press.

51.  Hoffmann S, de Vries RBM, Stephens ML, Beck NB, Dirven H, Fowle JR III, Goodman JE, HartungT, Kimber I, Lalu MM, Thayer K, Whaley P, Wikoff D and Tsaioun K. A primer on systematic reviews in toxicology. Archives of Toxicology 2017, 91:2551–2575. DOI 10.1007/s00204-017-1980-3. (IF 5.1)

52.  Kaesler S, Skabytska Y, Chen K-M, Kempf WE, Volz T, Köberle M, Wölbing F, Hein U, HartungT, Kirschning C, Röcken M and Biedermann T. Staphylococcus aureus-derived lipoteichoic acid induces temporary T-cell paralysis independent of Toll-like receptor 2. Journal of Allergy and Clinical Immunology 2017, 138:780-790.e6. doi: 10.1016/j.jaci.2015.11.043. (IF 11.5)   

53.  Kerecman Myers D, Goldberg AM, Poth A, Wolf MF, Carraway J McKim J, Coleman KP, Hutchinson R, Brown R, Krug HF, Bahinski A and HartungT. From in vivoto in vitro: the medical device testing paradigm shift, ALTEX, 34:479-500. (IF 4.1)

54.  Lee J, Choi J, Alpergin ESS, Zhao L, HartungT, Scafidi S, Riddle RC and Wolfgang MJ. Loss of hepatic fatty acid oxidation confers resistance to diet-induced obesity and glucose intolerance. Cell Reports 2017, 20:655–667. doi:  10.1016/j.celrep.2017.06.080. (IF 7.9)

55.  Leist M, Ghallab A, Graepel R, Marchan R, Hassan R, Hougaard, Bennekou S, Limonciel A, Vinken M, Schildknecht S, Waldmann T, Danen E, van Ravenzwaay B, Kamp H, Gardner I, Godoy P, Bois FY, Braeuning A, Reif R, Oesch F, Drasdo D, Höhme S, Schwarz M, HartungT, Braunbeck T, Beltman J, Vrieling H, Sanz F, Forsby A, Gadaleta D, Fisher C, Kelm J, Fluri D, Ecker G, Zdrazil B, Terron A, Jennings P, van der Burg B, Dooley S, Meijer AH, Willighagen E, Martens M, Evelo C, Mombelli E, Taboureau O, Mantovani A, Hardy B, Koch B, Escher S, van Thriel C, Cadenas C, Kroese D, van de Water B and Hengstler JG. Adverse outcome pathways: opportunities, limitations and open questions. Archives Toxicology 2017, 31:221–229. DOI 10.1007/s00204-017-2045-3.  (IF 5.1).

56.  Luechtefeld T and HartungT. Computational Approaches to Chemical Hazard Assessment. ALTEX 2017, 34:459-478. (IF 4.1)

57.  Maertens A, Bouhifd M, Zhao L, Odwin-DaCosta S, Kleensang A, Yager JD and HartungT. Metabolomic network analysis of estrogen-stimulated MCF-7 cells: a comparison of over-representation analysis, quantitative enrichment analysis and pathway analysis versus metabolite network analysis. Arch. Toxicol. 2017, 91:217-230. DOI: 10.1007/s00204-016-1695-x (IF 5.1)

58.  Myint L, Kleensang A, Zhao L, HartungT and Hansen KD. Joint bounding of peaks across samples improves differential analysis in mass spectrometry-based metabolomics. Analytical Chemistry 2017, 89:3517-3523. doi: 10.1021/acs.analchem.6b04719. (IF 5.6)

59.  Pamies D, Barreras P, Block K, Makri G, Kumar A, Wiersma D, Smirnova L, Zang C, Bressler J, Christian KM, Harris G, Ming G-L, Kyro K, Berlinicke C, Song H, Pardo CA, HartungT and Hogberg HT. A Human Brain Microphysiological System derived from iPSC to study central nervous system toxicity and disease. ALTEX 2017, 34:362-376. doi: 10.14573/altex.1609122. (IF 4.1)

60.  Pamies D, Bal-Price A, Simeonov A, Tagle D, Allen D, Gerhold D, Yin D, Pistollato F, Inutsuka T, Sullivan K, Stacey G, Salem H, Leist M, Daneshian M, Vemuri MC, McFarland R, Coecke S, Fitzpatrick SC, Lakshmipathy U, Mack A, Wang WB, Sekino Y, Kanda Y, Smirnova L and HartungT. Good Cell Culture Practice for stem cells and stem-cell-derived models. ALTEX 2017, 34:95-132. (IF 4.1)

61.  Pamies D and HartungT. 21stcentury cell culture for 21stcentury toxicology. Chem Res Toxicol 2017, 30:43–52. DOI: 10.1021/acs.chemrestox.6b00269 (IF 3.5).

62.  Pendse SN, Maertens A, Rosenberg M, Roy D, Fasani R, Vantangoli M, Madnick S, Boekelheide K, Fornace A Jr, Odwin S-A, Yager J, HartungT                                                    time-dependent transcriptional regulation of the estrogen pathway of toxicity. Arch. Toxicol. 2017, 91:1749–1762. doi: (IF 5.1)

63.  Ramirez T, Strigun A, Verlohner A, Huener H-A, Peter E, Herold M, Mellert W, Walk T, Spitzer M, HartungT, Kamp H and van Ravenzwaay B. Prediction of liver toxicity and mode of action using metabolomics in vitro. Arch. Toxicol. 2017, Sep 30. doi: 10.1007/s00204-017-2079-6. [Epub ahead of print]. (IF 5.1).

64.  Russo DP, Kim MT, Wang W, Pinolini D, Shende S, Strickland J, HartungT and Zhu H. CIIPro: a new read-across portal to fill data gaps using public large-scale chemical and biological data. Bioinformatics 2017, 33:464–466, doi: 10.1093/bioinformatics/btw640 (IF 5.8)

65.  Schmidt BZ, Lehmann M, Gutbier S, Nembo E, Noel S, Smirnova L, Forsby A, Hescheler J, Avci HX, HartungT, Leist M, Kobolák J and Dinnyés A. In vitro neurotoxicity screening:
an overview of cellular platforms and high-throughput technical possibilities. Arch. Toxicol. 2017, 91:1-33. DOI 10.1007/s00204-016-1805-9. [Epub ahead of print] (IF 5.1)

66.  Skardal A, Murphy S, Devarasetty M, Mead I, Kang H-W, Seol Y-J, Shrike Zhang Y, Ryon Shin S, Zhao L, Aleman J, Hall A, Shupe T, Kleensang A, Dokmeci M, Lee SJ, Jackson J, Yoo J, HartungT, Khademhosseini A, Soker S, Bishop C, and Atala A. Multi-tissue interactions in an integrated three-tissue organ-on-a-chip platform. Scientific Reports, 7, Article number: 8837 (2017) doi:10.1038/s41598-017-08879-x. (IF 5.6)

67.  Tong Z-B, Hogberg H, Kuo D, Sakamuru S, Xia M, Smirnova L, HartungT and Gerhold D. Characterization of three human cell line models for high-throughput neuronal cytotoxicity screening. J. Appl. Toxicol. 2017, 37:167-180. doi: 10.1002/jat.3334. (IF 2.6).

68.  van Ravenzwaay B, Jiang X, Luechtefeld T and HartungT. The Threshold of Toxicological Concern for prenatal developmental toxicity in rats and rabbits. Regulatory Pharmacology and Toxicology 2017, 88:157-172. doi: 10.1016/j.yrtph.2017.06.008.(2.0)


69.  Ankley G, Escher B, HartungT and Shah I. Pathway-based approaches for environmental monitoring and risk assessment. Environmental Science & Technology 2016, 50: 10295−10296. DOI: 10.1021/acs.est.6b04425 (IF 5.3).

70.  Ankley G, Escher B, HartungT and Shah I. Pathway-based approaches for environmental monitoring and risk assessment. Chem. Res. Toxicol. 2016, 29, 1789−1790. DOI: 10.1021/acs.chemrestox.6b00321 (IF 3.5)

71.  Ball N, Cronin MTD, Shen J, Adenuga MD, Blackburn K, Booth ED, Bouhifd M, Donley E, Egnash L, Freeman JJ, Hastings C, Juberg DR, Kleensang A, Kleinstreuer N, Kroese D, Lee AC, Luechtefeld T, Maertens A, Marty S, Naciff JM, Palmer J, Pamies D, Penman M, Richarz A-N, Russo DP, Stuard SB, Patlewicz G, van Ravenzwaay B, Wu S, Zhu H and HartungT. Toward Good Read-Across Practice (GRAP) guidance. ALTEX 2016, 33, 149-166. (IF 4.1)

72.  Benfenati E, Berggren E, Fritsche E, HartungT, Slikker W Jr, Spielm ann H, Test ai E, Tice RR, Tiramani M and Villenave R, 2016. Special issue: novel chemical hazard characterisation approaches. EFSA Journal 2016, 14(S1):s0506, 10 pp. doi:10.2903/j.efsa.2016.s0506.

73.  Bowman CE, Zhao L, HartungT and Wolfgang MJ. Requirement for the mitochondrial pyruvate carrier in mammalian development revealed by a hypomorphic allelic series. Molecular Cellular Biology, 2016, 36:2089-2104. doi:10.1128/MCB.00166-16 (IF 4.8)

74.  Busquet F, Zurlo J and HartungT. Can TTIP Improve Laboratory Animal Welfare in Safety Testing and 3Rs? ILAR J, 2016, 57:358-367. doi: 10.1093/ilar/ilw022. (IF 2.4)

75.  Busquet F, HartungT and Hubert P. La fin de l’animal cobaye. In: Matignin KL. Revolutions animales – comment les animaux sont deveus intelligents. 2016, Arte Editions, 411-414.

76.  da Silva CC, Presgrave OAF, HartungT, Lage de Moraes AM, Delgado IF. Applicability of the Monocyte Activation Test (MAT) for hyperimmune sera in the routine of the quality control laboratory: Comparison with the Rabbit Pyrogen Test (RPT). Toxicol. In Vitro 2016, 32:70–75. (IF 2.7)

77.  Fasani RA, Livi CB, Choudhury DR, Kleensang A, Bouhifd M, Pendse SN, McMullen PD, Andersen ME, HartungT and Rosenberg M. The Human Toxome Collaboratorium: a shared environment for multi-omic computational collaboration within a consortium. Frontiers in Pharmacology 2016, 6:322. doi: 10.3389/fphar.2015.00322. (IF 3.8)

78.  Ferrario D,Gribaldo Land Hartung T. Arsenic exposure and immunotoxicity: a review including the possible influence of age and sex. Curr Environ Health Rep 2016, 3:1-12. doi: 10.1007/s40572-016-0082-3.

79.  HartungT. E-Cigarettes and the need and opportunities for alternatives to animal testing. ALTEX 2016, 33:211-224. (IF 4.1)

80.  HartungT. Making big sense from big data in toxicology by read-across. ALTEX, 2016, 33:83-93. (IF 4.1)

81.  HartungT. Can we wait for e-cigarette trials? Chemistry World 2016, available at: 0.2)

82.  HartungT. E-cigarettes – the ugly duckling of public health? Scientific American 2016, 315(2):9-9. (IF 1.5)

83.  HartungT, Borel A and Schmitz G. Detecting the broad spectrum of pyrogens with the human whole-blood monocyte activation test. BioProcess International 2016, 14:38-56. 

84.  Hoffmann S, Hartung T and Stephens M. Evidence-based toxicology.Adv Exp Med Biol 2016, 856:231-241. (IF 2.2)

85.  Juberg DR, Knudsen TB, Sander M, Beck NB, Faustman EM, Mendrick DL, Fowle JR III, HartungT, Tice RT, Lemazurier E, Becker RA, Fitzpatrick SC, Daston GP, Harrill A, Hines RN, Keller DA, Lipscomb JC, Watson D, Bahadori T and Crofton KM. FutureTox III: Bridges for Translation. Toxicol Sci, 2016, 155:22-31 doi: 10.1093/toxsci/kfw194. (IF 4.3)

86.  Kilic O, Pamies D, Lavell E, HartungT, Bal-Price A, Hogberg HT, Quinones-Hinojosa A, Guerrero-Cazares H and Levchenko A. Microphysiological brain model enables analysis of neuronal differentiation and chemotaxis. Lab Chip 2016,16:4152-4162. DOI: 10.1039/C6LC00946H. (IF 6.1).

87.  Kleensang A, Vantangoli M, Odwin-DaCosta S, Andersen ME, Boekelheide K, Bouhifd M, Fornace AJ Jr, Livi CB, Madnick S, Maertens A, Zhao L, Rosenberg M, Yager JD and HartungT. Genetic variability in a frozen batch of MCF-7 cells invisible in routine authentication affecting cell function. Scientific Reports 6:28994-28994. (IF 5.6)

88.  Luechtefeld T, Maertens A, Russo DP, Rovida C, Zhu H and HartungT. Global analysis of publicly available safety data for 9,801 substances registered under REACH from 2008-2014. ALTEX 2016, 33, 95-109. (IF 4.1)

89.  Luechtefeld T, Maertens A, Russo DP, Rovida C, Zhu H and HartungT. Analysis of public oral toxicity data from REACH registrations 2008-2014. ALTEX 2016, 33, 111-122. 4.1)

90.  Luechtefeld T, Maertens A, Russo DP, Rovida C, Zhu H and HartungT. Analysis of Draize eye irritation testing and its prediction by mining publicly available 2008-2014 REACH data. ALTEX 2016, 33, 123-134. 4.1)

91.  Luechtefeld T, Maertens A, Russo DP, Rovida C, Zhu H and HartungT. Analysis of publically available skin sensitization data from REACH registrations 2008-2014. ALTEX 2016, 33, 135-148. 4.1)

92.  Marx U, Andersson TB, Bahinski A, Beilmann M, Beken S, Cassee FR, Cirit M, Daneshian M, Fitzpatrick S, Frey O, Gaertner C, Giese C, Griffith L, HartungT, Heringa MB, Hoeng J, de Jong WH, Kojima H, Kuehnl J, Luch A, Maschmeyer I, Sakharov D, Sips AJAM, Steger-Hartmann T, Tagle DA, Tonevitsky A, Tralau T, Tsyb S, van de Stolpe A, Vandebriel R, Vulto P, Wang J, Wiest J, Rodenburg M and Roth A. Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing using animals. ALTEX 2016, 33:272-321. doi: 10.14573/altex.1603161(IF 4.1)

93.  Pistollato F, Ohayon EL, Lam A, Langley GR, Novak T, Pamies D, Perry G, Trushina E, Williams RSB, Roher AE, HartungT, Harnad S, Barnard N, Morris MC, Lai M-C, Merkley R and Chandrasekera PC. Alzheimer disease research in the 21st century: past and current failures, new perspectives and funding priorities. Oncotarget 2016, 7:38999-39016. doi: 10.18632/oncotarget.9175. (IF 6.4)

94.  Samuel GO, Hoffmann S, Wright R, Lalu MM, Patlewicz G, Becker RA, DeGeorge GL, Fergusson D, HartungT, Lewis J and Stephens M. Guidance on assessing the methodological and reporting quality of toxicologically relevant studies: a scoping review. Environment International 2016, 92-93:630-646. (IF 5.6)

95.  Smirnova L, Harris G, Delp J, Valadares M, Pamies D, Hogberg HT, Waldmann T, Leist M and HartungT. A LUHMES 3D dopaminergic neuronal model for neurotoxicity testing allowing long-term exposure and cellular resilience analysis. Arch Toxicol 2016, 90:2725-2743. DOI 10.1007/s00204-015-1637-z. (IF 5.1)

96.  Stephens ML, Betts K, Beck NB, Cogliano V, Dickersin K, Fitzpatrick S, Freeman J, Gray G, HartungT, McPartland J, Rooney AA, Scherer RW, Verloo D and Hoffmann S. The emergence of systematic review in toxicology. Toxicol Sci, 2016, 152:10–16. doi: 10.1093/toxsci/kfw059(IF 4.3)

97.  Tsaioun K, Blaauboer BJ and HartungT. Evidence-based absorption, distribution, metabolism, excretion and toxicity (ADMET) and the role of alternative methods. ALTEX 2016, 33:343-358. (IF 4.1)

98.  Zhu H, Bouhifd M, Kleinstreuer N, Kroese ED, Liu Z, Luechtefeld T, Pamies D, Shen J, Strauss V, Wu S and HartungT. Supporting read-across using biological data. ALTEX 2016, 33, 167-182. (IF 4.1)


99.  Bal-Price A, Crofton KM, Leist M, Allen S, Arand M, Buetler T, Delrue N, FitzGerald RE, HartungT, Heinonen T, Hogberg H, Hougaard Bennekou S, Lichtensteiger W, Oggier D, Paparella M, Axelstad M, Piersma A, Rached E, Schilter B, Schmuck G, Stoppini L, Tongiorgi E, Tiramani M, Monnet-Tschudi F, Wilks MF, Ylikomi T and Fritsche E. International STakeholder NETwork (ISTNET): Creating a Developmental Neurotoxicity Testing (DNT) Roadmap for Regulatory Purposes. Arch. Toxicol. 2015, 89:269–287. (IF 5.2)

100.Borel A, Holtkamp B, Schmitz G and HartungT. Improved detection of pyrogens using the monocyte activation test. Pharmaceut. Rev. 2015, May:32-33.

101.Bouhifd M, Beger R, Flynn T, Guo L, Harris G, Hogberg HT, Kaddurah-Daouk R, Kamp H, Kleensang A, Maertens A, Odwin-DaCosta S, Pamies D, Robertson D, Smirnova L, Sun J, Zhao L and HartungT. Quality Assurance of Metabolomics. ALTEX, 2015, 32:319-326.(IF 4.1)

102.Bouhifd M, Andersen ME, Baghdikian C, Boekelheide K, Crofton KM, Fornace AJ Jr., Kleensang A, Li H, Livi CB, Maertens A, McMullen PD, Rosenberg M, Thomas R, Vantangoli M, Yager JD, Zhao L and HartungT. The Human Toxome project. ALTEX 2015, 32:112-124. (IF 4.1)

103.Daneshian M, Busquet F, HartungT and Leist M. Animal use for science in Europe. ALTEX, 2015, 32:261-274. (IF 4.1)

104.Gordon S, Daneshian M, Bouwstra J, Caloni F, Constant S, Davies DE, Dandekar G, Guzman CA, Fabian E, Haltner E, HartungT, Hasiwa N, Hayden P, Kandarova H, Khare S, Krug HF, Kneuer C, Leist M, Lian G, Marx U, Metzger M, Ott K, Prieto P, Roberts MS, Roggen EL, Tralau T, van den Braak C, Walles H and Lehr C-M. Non-animal models of epithelial barriers (skin, intestine and lung) in research, industrial applications and regulatory toxicology. ALTEX 2015, 32:327-378. (IF 4.1)

105.HartungT. The human whole blood pyrogen test – lessons learned in twenty years. ALTEX 2015, 32:79-100. (IF 4.1)

106.HartungT, Borel A and Schmitz G. The whole blood monocyte activation test: reliable detection of non-endotoxin pyrogens. Innovat. Pharmaceut. Technol. 2015, in press.

107.HartungT. Green Toxicology. In: Gocht T and Schwarz M. SEURAT-1: The proof-of-concept case studies. 2015, 59-67.

108.HartungT. Toxicity testing of nanomaterials: case for in vitro tests. (chapter 5), 113-152. In: Fadeel B (Ed.) Handbook of Safety Assessment of Nanomaterials: From Toxicological Testing to Personalized Medicine. 2015, Pan Stanford Publishing Pte. Ltd., Singapore.

109.HartungT. Safety First. Innovations in Pharmaceutical Technology, Issue 54:40-43.

110.Head S, Shi W, Zhao L, Gorshkov K, Pasunooti K, Chen Y, Deng Z, Li R-J, Shim JS, Tan W, HartungT, Zhang J, Zhao J, Colombini M and Liu JO. The antifungal drug itraconazole targets VDAC1 to modulate the AMPK/mTOR signaling axis in endothelial cells. Proc. Natl. Acad. Sci. U S A 2015, 112:E7276-85. doi: 10.1073/pnas.1512867112. (IF 9.4)

111.Linkov I, Massey O, Keisler J, Rusyn I and HartungT. From “weight of evidence” to quantitative data integration using multicriteria decision analysis and Bayesian methods. ALTEX 2015, 32: 3-8. doi: (IF 4.1)

112.Luechtefeld T, Maertens A, McKim J, HartungT, Kleensang A and Sá-Rocha V. Probabilistic hazard assessment for skin sensitization potency by dose response modeling using feature elimination instead of QSAR. J. Appl. Toxicol. 2015, 35:1361–1371. (IF 2.6)

113.Maertens A, Luechtefeld T, Kleensang A and HartungT. MPTP’s pathway of toxicity indicates central role of transcription factor SP1. Arch. Toxicol. 2015, 89:743-755. doi: 10.1007/s00204-015-1509-6. (IF 5.1)

114.Rovida C, Alépée N, Api AM, Basketter DA, Bois FY, Caloni F, Corsini E, Daneshian M, Eskes C, Ezendam J, Fuchs H, Hayden P, Hegele-Hartung C, Hoffmann S, Hubesch B, Jacobs MN, Jaworska J, Kleensang A, Kleinstreuer N, Lalko J, Landsiedel R, Lebreux F, Luechtefeld T, Locatelli M, Mehling A, Natsch A, Pitchford JW, Prater D, Prieto P, Schepky A, Schuurmann, G, Smirnova L, Toole C, van Vliet E, Weisensee D and HartungT. Integrated Testing Strategies (ITS) for Safety Assessment. ALTEX 2015, 32:171-181. doi: 4.1)

115.Rovida C, Asakura C, Daneshian M, Hofman-Huether H, Leist M, Meunier L, Reif D, Rossi A, Schmutz M, Valentin J-P, Zurlo J and HartungT. Toxicity testing in the 21stcentury beyond environmental chemicals. ALTEX 2015, 32:25-40. doi: (IF 4.1)

116.Sauer JM, HartungT, Leist M, Knudsen TB, Hoeng J and Hayes AW. Systems Toxicology: The Future of Risk Assessment. International Journal of Toxicology 2015, 34:346–348. 1.2)

117.Smirnova L, Harris G, Leist M and HartungT. Cellular Resilience. ALTEX, 2015, 32:247-260. (IF 4.1)

118.Zhao L and HartungT. Metabonomics and toxicology. Meth. Mol. Biol. 2015, 1277:209-231. (IF 1.3)


119.Alépée N, Bahinski T, Daneshian M, De Wever B, Fritsche E, Goldberg A, Hansmann J, HartungT, Haycock J, Hogberg H, Hoelting L, Kelm JM, Kadereit S, McVey E, Landsiedel R, Leist M, Lübberstedt M, Noor F, Pellevoisin C, Petersohn D, Pfannenbecker U, Reisinger K,  Ramirez T, Rothen-Rutishauser B, Schäfer-Korting M, Zeilinger K and Zurich M-G. State-of-the-art of 3D cultures (organs-on-a-chip) in safety testing and pathophysiology – a t4report. ALTEX 2014, 31:441-477. (IF 4.1)

120.Andersen M, Betts K, Dragan Y, Fitzpatrick S, Goodman JL, HartungT, Himmelfarb J, Ingber DE, Jacobs A, Kavlock R, Kolaja K, Stevens JL, Tagle D, Taylor DL and Throckmorton D. Developing microphysiological systems for use as regulatory tools - challenges and opportunities. ALTEX 2014, 31:364-367. (IF 4.1)

121.Andersen M, Betts K, Dragan Y, Fitzpatrick S, Goodman JL, HartungT, Himmelfarb J, Ingber DE, Jacobs A, Kavlock R, Kolaja K, Stevens JL, Tagle D, Taylor DL and Throckmorton D. Developing microphysiological systems for use as regulatory tools - challenges and opportunities - extended online version. ALTEX 2014. Available at: 4.1)

122.Bale AS, Kenyon E, Flynn TJ, Lipscomb JC, Mendrick DL, HartungT, and Patton GW. Correlating in vitro data to in vivo findings for risk assessment. ALTEX 2014, 31:79-90 (IF 4.1)

123.Bouhifd M, Hogberg HT, Kleensang A, Maertens A, Zhao L and HartungT. Mapping the Human Toxome by systems toxicology. Basic Clin. Pharmacol. Toxicol. 2014, 115:1-8, Doi: 10.1111/bcpt.12198 (IF 2.1).

124.Busquet F, Palopoli M and HartungT. Regulatory toxicology – progress in law. In: Town W. and Currano JN (Ed) “Science and the Law: Analytical data in support of regulation in health, food, and the environment”, Amer Chem Soc. 2014, Vol. 1147, 51-69.

125.Ferrario D, Brustio R and HartungT.Glossary of reference terms for alternative test methods and their validation. ALTEX 2014, 31:319-335. (IF 4.1)

126.HartungT. 3D - A new dimension of in vitro research. Advanced Drug Delivery Reviews, Preface Special Issue "Innovative tissue models for in vitro drug development". 2014, 69:vi. (IF 12.9)

127.HartungT and Stephens M. Toxicity Testing in the 21st Century, Approaches to Implementation. In: Wexler P. Encyclopedia of Toxicology, 3rdedition, 2014, ElsevierInc., Academic Press, 673-675.

128.HartungT. The wizard of the 3Rs. ALTEX 2014, 31:547-548. (IF 4.1)

129.HartungT. Toward mechanistic validation. In: Gocht T and Schwarz M. SEURAT-1: The proof-of-concept case studies. 2014, 62-72.

130.Hoffmann S, Stephens M and HartungT. Evidence-based Toxicology. In: Wexler P (Ed). Encyclopedia of Toxicology, 3rd edition vol 2. Elsevier Inc., Academic Press, 2014, 565–567.

131.Hoffmann S, HartungT and Stephens M. Evidence-based toxicology. In: Validating Alternative Methods for Toxicity Testing, 2014, Springer

132.Hogberg HT and HartungT. Regulatory toxicology – progress in science. In: Town W. and Currano JN (Ed) “Science and the Law: Analytical data in support of regulation in health, food, and the environment”, Amer Chem Soc. 2014, Vol. 1147, 95-110.

133.Juberg DR, Borghoff SJ, Becker RA, Casey W, HartungT, Holsapple M, Marty S, Mihaich E, Van Der Kraak G, Wade MG, Willett CE, Andersen M, Borgert C, Coady K, Dix D, Dourson M, Gray E, Lamb J, Ortego L, Schug T, Toole C, Zorrilla L, Kroner O, Patterson J, Rinckel L and Jones B. Lessons Learned, Challenges, and Opportunities: The U.S. Endocrine Disruptor Screening Program. ALTEX 2014, 31:63-78. (IF 4.1)

134.Kleensang A, Maertens A, Rosenberg M, Fitzpatrick S, Lamb J, Auerbach S, Brennan R, Crofton KM, Gordon B, Fornace AJ Jr., Gaido K, Gerhold D, Haw R, Henney A, Ma'ayan A, McBride M, Monti S, Ochs MF, Pandey A, Sharan R, Stierum R, Tugendreich S, Willett C, Wittwehr C, Xia J, Patton GW, Arvidson K, Bouhifd M, Hogberg HT, Luechtefeld T, Smirnova L, Zhao L, Adeleye Y, Kanehisa M, Carmichael P, Andersen E. M, HartungT. Pathways of Toxicity. ALTEX 2014, 31:53-61. doi: 10.14573/altex.1309261 (IF 4.1)

135.Krug AK, , Ivanova V, Förster S, Jagtap S, Meiser J, Leparc G, Schildknecht S, Adam M, Hiller K, Farhan H, Brunner T, HartungT, Sachinidis A, and Leist M. Transcriptional and metabolic adaptation of human neurons to the mitochondrial toxicant MPP+. Cell Death Disease, 2014, 5, e1222. doi:10.1038/cddis.2014.166. (IF 6.0)

136.Leist M, Hasiwa N, Rovida C, Daneshian M, Basketter D, Kimber I, Clewell H, Gocht T, Goldberg A, Busquet F, Rossi A-M, Schwarz M, Stephens M, Taalman R, Knudsen TB, McKim J, Harris G, Pamies D and HartungT. Consensus report on the future of animal-free systemic toxicity testing. ALTEX 2014, 31:341–356. (IF 4.1)

137.Maertens A, Anastas N, Spencer PJ, Stephens M, Goldberg A and HartungT. Green Toxicology. ALTEX 2014, 31:243-249. (IF 4.1)

138.Pamies D, HartungT and Hogberg HT. Biological and medical applications of a brain-on-a-chip. Experimental Biology and Medicine, 2014 Jun 9. pii: 1535370214537738. (IF 2.8)

139.Patlewicz G, Ball N, Becker RA, Blackburn K, Booth E, Cronin M, Kroese D, Steup D, van Ravenzwaay B and HartungT. Read-across approaches - misconceptions, promises and challenges ahead. ALTEX 2014, 31:387-396. (IF 4.1)

140.Rivera-Mariani FE, Vysyaraju K, Negherbon J, Levetin E, Horner WE, HartungT and Breysse PN. Comparison of the interleukin-1-inducing potency of allergenic spores from higher fungi (basidiomycetes) in a cryopreserved human whole blood system. Int. Arch. Allergy Immunol. 2014, 163:154-62. (IF 2.3)

141.Simon TW,Simons SS Jr,Preston RJ,Boobis AR,Cohen SM,Doerrer NG,Fenner-Crisp PAMcMullin TS,McQueen CA,Rowlands JC;RISK21 Dose-Response Subteam.The use of mode of action information in risk assessment: quantitative key events/dose-response framework for modeling the dose-response for key events. Crit Rev Toxicol. 2014, 44 Suppl 3:17-43. doi: 10.3109/10408444.2014.931925. (IF 5.1)

142.Smirnova L, Hogberg HT, Leist M, and HartungT. Developmental neurotoxicity – challenges in the 21st century and in vitro opportunities. ALTEX 2014, 31:129-156. (IF 4.1)

143.Tollefsen KE, Scholz S, Cronin MT, Edwards SW, de Knecht J, Crofton K, Garcia-Reyero N, HartungT, Worth A, and Patlewicz G. Applying Adverse Outcome Pathways (AOPs) to support Integrated Approaches to Testing and Assessment (IATA). Reg. Toxicol. Pharmacol. 2014, 70:629-640. (IF 1.1)

144.van Vliet E, Daneshian M, Beilmann M, Davies A, Fava E, Fleck R, Julé Y, Kansy M, Kustermann S, Macko P, Mundy W, Roth A, Shah I, Uteng M, van de Water B, HartungT and Leist M. Current approaches and future role of high content imaging in safety sciences and drug discovery. ALTEX 2014, 31:479-493.(IF 4.1)

145.Willett C, Caverly Rae J, Goyak KO, Minsavage G, Westmoreland C, Andersen M, Avigan M, Duché D, Harris G, HartungT, Jaeschke H, Kleensang A, Landesmann A, Martos S, Matevia M, Toole C, Rowan A, Schultz T, Seed J, Senior J, Shah I, Subramanian K, Vinken M and Watkins P. Building Shared Experience to Advance Practical Application of Pathway-Based Toxicology: Liver Toxicity Mode-of-Action. ALTEX 2014, 31:500-519. (IF 4.1)


146.Bouhifd M, HartungT, Hogberg HT, Kleensang A and Zhao L. Review: Toxicometabolomics. J. Appl. Toxicol. 2013, 33:1365-1383. DOI 10.1002/jat.2874. (IF 2.6).

147.Daneshian M, Botana LM, Dechraoui Bottein M-Y, Buckland G, Campàs M, Dennison N, Dickey RW, Diogène J, Fessard V, HartungT, Humpage A, Leist M, Molgó J, Quilliam MA, Rovida C, Suarez-Isla BA, Tubaro A, Wagner K, Zoller O, and Dietrich D. A roadmap for hazard monitoring and risk assessment of marine biotoxins on the basis of chemical and biological test systems. ALTEX 2013, 30, 487-545. (IF 4.1)

148.Davis M, Boekelheide K, Boverhof DR, Eichenbaum G, HartungT, Holsapple MP, Jones TW, Richard A, and Watkins PB. The new revolution in toxicology: The good, the bad, and the ugly. Annals of the New York Academy of Sciences 2013, 1278: 11–24. (IF 4.4)

149.HartungT. Look Back in anger – what clinical studies tell us about preclinical work. ALTEX 2013, 30:275-291.(IF 4.1)

150.HartungT, Luechtefeld T, Maertens A and Kleensang A. Integrated Testing Strategies for Safety Assessments. ALTEX 2013, 30:3-18. (IF 4.1)

151.HartungT, Stephens M and Hoffmann S. Mechanistic validation. ALTEX 2013, 30:119-130. (IF 4.1)

152.HartungT. From alternative methods to a new regulatory toxicology. ALTEX Proceedings 2, 21-35.

153.HartungT, Hasiwa N, Daneshian M, Holtkamp B, Schmitz G and Hossfeld A. Eine wirklich humane Bestimmung von Endotoxinen und Nicht-Endotoxin-Pyrogenen. [A truly human(e) determination of endotoxin and non-endotoxin pyrogens] PharmInd 2013, 75:825-834.

154.HartungT and Corsini E. Immunotoxicology: challenges in the 21stcentury and in vitro opportunities. ALTEX 2013, 30:411-426. (IF 4.1)

155.Hasiwa N, Daneshian M, Bruegger P, Fennrich S, Fleck R, Hochadel A, Hoffmann S, Rivera-Mariani FE, Rockel C, Schindler S, Spreitzer I, Stoppelkamp S, Vysyaraju K and HartungT. Evidence for the detection of non-endotoxin pyrogens by the whole blood monocyte activation test. ALTEX 2013, 30:169-208. (IF 4.1)

156.Hogberg HT, Bressler J, Christian KM, Harris G, Makri G, O’Driscoll C, Pamies D, Smirnova L, Wen Z and HartungT. Toward a 3D model of human brain development for studying gene/environment interactions. Stem Cell Research & Therapy 2013, 4(Suppl 1):S4:1-7. Available at: 3.7)

157.Judson R, Kavlock R, Martin M, Reif D, Houck K, Knudsen T, Richard A, Tice R, Whelan M, Xia M, Huang R, Austin C, Daston G, HartungT, Fowle JR III, Wooge W, Tong W and Dix D. Perspectives on Validation of High-Throughput Pathway-Based Assays Supporting the 21st Century Toxicity Testing Vision ALTEX 2013, 30:51-66. (IF 4.1)

158.Leist M and HartungT. Inflammatory findings on species extrapolations: humans are definitely no 70-kg mice. Arch. Toxicol. 2013, 87:563–567. doi:10.1007/s00204-013-1038-0. (IF 5.2)

159.Leist M and HartungT. Reprint: Inflammatory findings on species extrapolations: humans are definitely no 70-kg mice. ALTEX 2013, 30:227-230. (IF 4.1)

160.Ramirez T, Daneshian M, Kamp H, Bois FY, Clench MR, Coen M, Donley B, Fischer SM, Ekman DR, Fabian E, Guillou C, Heuer J, Hogberg HT, Jungnickel H, Keun HC, Krennrich G, Krupp E, Luch A, Noor F, Peter E, Riefke B, Seymour M, Skinner N, Smirnova L, Verheij E, Wagner S, HartungT, van Ravenzwaay B and Leist M. Metabolomics in Toxicology and Preclinical Research. ALTEX 2013, 30:209-225. (IF 4.1)

161.Saldutti LP, Beyer BK, Breslin W, Brown TR, Chapin RE, Campion S, Enright B, Faustman E, Foster PMD, HartungT, Kelce W, Kim JH, Loboa EG, Piersma AH, Seyler D, Turner KJ, Yu H, Yu X and Sasaki JC. In Vitro Testicular Toxicity Models: Opportunities for Advancement via Biomedical Engineering Techniques. ALTEX 2013, 30:353-377. (IF 4.1)

162.Scholz S, Sela E, Blaha L, Braunbeck T, Galay-Burgos M, García-Franco M, Guinea J, Klüver N, Schirmer K, Tanneberger K, Tobor-Kapłon M, Witters H, Belanger S, Benfenati E, Creton S, Cronin MTD, Eggen RIL, Embry M, Ekman D, Gourmelon A, Halder M, Hardy B, HartungT, Hubesch B, Jungmann D, Lampi MA, Lee LL, Léonard M, Küster E, Lillicrap A, Luckenbach T, Murk AJ, Navas JM, Peijnenburg W, Repetto G, Salinas E, Schüürmann G, Spielmann H, Tollefsen KE, Walter-Rohde S, Whale G, Wheeler JR and Winter MJ. A European perspective on alternatives to animal testing for environmental hazard identification and risk assessment. Regulat. Toxicol. Pharmacol. 2013, 67:506-530. doi: 10.1016/j.yrtph.2013.10.003. (IF 2.4)

163.Stephens ML, Andersen M, Becker RA, Betts K, Boekelheide K, Carney E, Chapin R, Devlin D, Fitzpatrick S, Fowle JR, Harlow P,Hartung T, Hoffmann S, Holsapple M, Jacobs A, Judson R, Naidenko O, Pastoor T, Patlewicz G, Rowan A, Scherer R, Shaikh R, Simon T, Wolf D and Zurlo J. Evidence-based Toxicology for the 21stCentury: Opportunities and Challenges. ALTEX 2013, 30:74-104. (IF 4.1)

164.van Vliet E, Eixarch E, Illa M, Arbat-Plana A, González-Tendero A, Hogberg HT, Zhao L, HartungT and Gratacos E. Metabolomics reveals metabolic alterations by intrauterine growth restriction in the fetal rabbit Therap. PLoS ONE 2013, 8: e64545. (IF 3.7)


165.Basketter DA, Clewell H, Kimber I, Rossi A, Blaauboer B, Burrier R, Daneshian M, Eskes C, Goldberg A, Hasiwa N, Hoffmann S, Jaworska J, Knudsen TB, Landsiedel R, Leist M, Locke P, Maxwell G, McKim J, McVey EA, Ouédraogo G, Patlewicz G, Pelkonen O, Roggen E, Rovida C, Ruhdel I, Schwarz M, Schepky A, Schoeters G, Skinner N, Trentz K, Turner M, Vanparys P, Yager J, Zurlo J and HartungT. A roadmap for the development of alternative (non-animal) methods for systemic toxicity testing. ALTEX 2012, 29:3-89. (IF 4.1)

166.Ferrario D and Rabbit RR [Hartung T]. Analysis of the proposed EU regulation concerning biocide products and its opportunities for alternative approaches and a toxicology for the 21st century (t4 report). ALTEX 2012, 29: 157–172. (IF 4.1)

167.HartungT, van Vliet E, Jaworska J, Bonilla L, Skinner N and Thomas R. Systems toxicology. ALTEX 2012, 29: 119-128. (IF 4.1)

168.HartungT, and Zurlo J. Alternative approaches for medical countermeasures to biological and chemical terrorism and warfare. ALTEX 2012, 29: 251–260.(IF 4.1)

169.HartungT. 21stcentury toxicology – 88 years left? Chemistry World June 2012, 39.

170.Leist M, Hasiwa M, Daneshian M and HartungT. Validation and quality control of replacement alternatives – current status and future challenges. Toxicological Research 2012, 1:8, DOI: 10.1039/C2TX20011B.

171.Rockel C andHartung, T. Systematic review of membrane components of Gram-positive bacteria responsible as pyrogens for inducing human monocyte / macrophage cytokine release. Frontiers in Pharmacology, 2012, 3. DOI=10.3389/fphar.2012.00056. available at:  URL= (IF 3.8)

172.Rossini GP and HartungT. Towards tailored assays for cell-based approaches to toxicity testing. ALTEX 2012, 29:359-372. (IF 4.1)


173.Daneshian M, Akbarsha MA, Blaauboer B, Caloni F, Cosson P, Curren R, Goldberg A, Gruber F, Ohl F, Pfaller W, van der Valk J, Vinardell P, Zurlo J, HartungT and Leist M. A framework program for the teaching of alternative methods (replacement, reduction, refinement) to animal experimentation.ALTEX 2011, 28:341-352. (IF 4.1) 

174.Dehus O, Pfitzenmaier M, Stuebs G, Fischer N, Schwaeble W, Morath S, HartungT, Geyer A and Hermann C. Growth temperature-dependent expression of structural variants of Listeria monocytogenes lipoteichoic acid. Immunobiol. 2011, 216:24-31. (IF 2.8)

175.Hasiwa N, Bailey J, Clausing P, Daneshian M, Eileraas M, Farkas S, Gyertyán I, Hubrecht R, Kobel W, Krummenacher G, Leist L, Lohi H, Miklósi A, Ohl F, Olejniczak K, Schmitt G, Sinnett-Smith P, Smith D, Wagner K, Yager JD, Zurlo J and HartungT. Critical evaluation of the use of dogs in biomedical research and testing in Europe. ALTEX 2011, 28:326-340. (IF 4.1)

176.HartungT, Blaauboer GJ, Bosgra S, Carney E, Coenen J, Conolly RB, Corsini E, Green S, Faustman EM, Gaspari A, Hayashi M, Hayes AW, Hengstler JG, Knudsen LE, Knudsen TB, McKim JM, Pfaller W and Roggen EL. An expert consortium review of the EC-commissioned report “Alternative (Non-Animal) Methods for Cosmetics Testing: Current Status and Future Prospects – 2010”.ALTEX 2011, 28, 183-209. (IF 4.1)

177.HartungT. From alternative methods to a new toxicology. Eur. J. Pharmaceutics Biopharmaceutics, 2011, 77:338–349. (IF 3.8)

178.HartungT and McBride M. Food for thought… on mapping the human toxome. ALTEX 2011, 28, 83-93. doi: 10.14573/altex.2011.2.083 (IF 4.1)

179.HartungT and Sabbioni E. Alternative in vitro assays in nanomaterial toxicology. WIREs Nanomed. Nanobiotechnol. 2011, 3:545-573. DOI: 10.1002/wnan.153 (IF 6.9)

180.Rockel C, HartungT and Hermann C. Different S. aureus whole bacteria mutated in putative pro-inflammatory membrane components have similar cytokine-inducing activity, Immunobiol. 2011, 216:316-321. (IF 2.8)

181.Rovida C, Longo F, and RabbitRR [Hartung T]. How are reproductive toxicity and developmental toxicity addressed in REACH dossiers? ALTEX 2011, 28:273-294. (IF 4.1)

182.Silbergeld EK, Contreras EQ,HartungT, Hirsch C, Hogberg H, Jachak AC, Jordan W, Landsiedel R, Morris J, Patri A, Pounds JG, de Vizcaya Ruiz A, Shvedova A, Tanguay R, Tatarazako N, van Vliet E, Walker NJ, Wiesner M, Wilcox N and Zurlo J. Nanotoxicology: “the end of the beginning” – Signs on the roadmap to a strategy for assuring the safe application and use of nanomaterials. ALTEX 2011, 28, 236-241. (IF 4.1)


183.Bal-Price AK, Hogberg HT, Buzanska L, Lenas P, van Vliet E and HartungT. In vitro developmental neurotoxicity (DNT) testing: Relevant models and endpoints. Neurotox. 2010, 31:545-554. (IF 2.7)

184.Basketter DA, Kimber I and HartungT. The evolution of validation: a commentary. Cutaneous Ocular Toxicol. 2010, 29:1-3. (IF 4.1)

185.Bottini AA and HartungT. The economics of animal testing. ALTEX Special Issue 2010, 27:67-77. (IF 4.1)

186.Bunk S, Sigel S, Metzdorf D, Sharif O, Triantafilou K, Triantafilou M, HartungT, Knapp S and von Aulock S. Internalization and co-receptor expression are critical for TLR2-mediated recognition of lipoteichoic acid in human peripheral blood. J. Immunol. 2010, 185:3708-3717. (IF 5.5)

187.Daneshian M, Leist M, HartungT. Center for alternatives to animal testing – Europe (CAAT-EU): a transatlantic bridge for the paradigm shift in toxicology. ALTEX 2010, 27:63-69. (IF 4.1)

188.Daneshian M, Leist M, HartungT. Das Center for Alternatives to Animal Testing – Europe (CAAT-EU): eine transatlantische Brücke für den Paradigmenwechsel in der Toxikologie. ALTEXethik 2010, 2, 90. (IF 4.1)

189.Di Mauro C, Bouchon S, Logtmeijer C, Nordvik JP, Pride R and HartungT. Structured approach to identifying European critical infrastructures. Int. J. Critical Infrastructures, 2010, 6:277-292. 

190.Forti E, Bulgheroni A, Cetin Y, HartungT, Jennings P, Pfaller W and Prieto P. Characterisation of cadmium chloride induced molecular and functional alterations in bronchial epithelial cells. Cell. Physiol. Biochem. 2010, 25:159-168. (IF 3.4)

191.HartungT. Comparative analysis of the revised Directive 2010/63/EU for the protection of laboratory animals with its predecessor 86/609/EEC – a t4report. ALTEX 2010, 27:285-303. (IF 4.1)

192.HartungT. Evidence based-toxicology – the toolbox of validation for the 21st century? ALTEX 2010, 27:241-251. (IF 4.1)

193.HartungT. Lessons learned from alternative methods and their validation for a new toxicology in the 21st century. J. Toxicol. Env. Health 2010, 13:277-290. (IF 3.9)

194.HartungT. Food for thought… on alternative methods for chemical safety testing. ALTEX 2010, 27, 3-14. (IF 4.1)

195.HartungT. Food for thought… on alternative methods for nanoparticle safety testing. ALTEX 2010, 27:87-95.(IF 4.1) 

196.HartungT, Bruner L, Curren R, Eskes C, Goldberg A, McNamee P, Scott L and Zuang V. First alternative method validated by a retrospective weight-of-evidence approach to replace the Draize eye test for the identification of non-irritant substances for a defined applicability domain. ALTEX 2010, 27, 43-51. (IF 4.1)

197. HartungT and Koeter H. Congress Chairmen´s Preface. ALTEX Special Issue 2010, 1-2. (IF 4.1)

198. Hartung, T. Vor- und Nachdenkliches… zu Alternativmethoden für die Sicherheitsprüfung von Chemikalien. ALTEXethik 2010, 2, 87. (IF 4.1) 

199. Hartung, T, Bruner L, Curren R, Eskes C, Goldberg A, McNamee P, Scott L and Zuang V. Erste Alternativmethode zum Ersatz des Draize Augentests zur Identifizierung nicht-irritativer Substanzen für eine definierte Applikationsdomäne durch einen retrospektiven weight-of-evidence-Ansatz validiert. ALTEX 2010, ALTEXethik 2010, 2, 89. (IF 4.1)

200. Hartung, T. Vor- und Nachdenkliches… zu Alternativmethoden für die Sicherheitsprüfung von Nanopartikeln. ALTEXethik 2010, 2, 91. (IF 4.1) 

201. HartungT. Evidenz-basierte Toxikologie – die richtige Methodensammlung für Validierung im 21. Jahrhundert? ALTEXethik 2010, 2, 102. (IF 4.1)

202. HartungT. Vergleichende Analyse der überarbeiteten Richtlinie 2010/63/EU für den Schutz von Labortieren mit der abgelösten Richtlinie 86/609/EEC – ein t4Bericht. ALTEXethik 2010, 2, 103. (IF 4.1)

203. Hogberg HT, Kinsner-Ovaskainen A, Coecke S, HartungT and Bal-Price AK.mRNA expression is a relevant tool to identify developmental neurotoxicants using an in vitro approach. Tox. Sci. 2010, 113:95-115. (IF 4.3)

204. Holtkamp B, Schmitz G and HartungT. In vitro-Pyrogentest - Nachweis eines breiten Pyrogenspektrums im Monozyten-Aktivierungstest. Biospektrum 2010, 16:779-781.

205. Presgrave O, Eskes C, Presgrave R, Alves E, Freitas JC, Caldeira C, Gimines I, Silva R, Nogueira S, Nunes J, Rivera E, Sá-Rocha V, Coecke S and HartungT. A Proposal to Establish a Brazilian Center for Validation of Alternative Methods (BraCVAM). ALTEX Special Issue 2010, 27:159-161. (IF 4.1)


206. Bottini AA and HartungT. Food for thought… on economics of animal testing. ALTEX 2009, 26:3-16. (IF 4.1)

207. Bottini AA and HartungT. Vor- und Nachdenkliches… zu ökonmischen Aspekten von Tierversuchen. ALTEX ethik 2009, 1:94-99. (IF 4.1)

208. Bulgheroni A, Kinsner-Ovaskainen A, Hoffmann S, HartungT and Prieto P. Estimation of acute oral toxicity using no adverse effect level (NOAEL) from the 28-day repeated dose toxicity studies in rats. Reg. Tox. Pharmacol. 2009, 53:16-19. (IF 2.1)

209. Corvi R and Hartung T. Alternative in vitro methods for carcinogenicity and mutagenicity. Exp. Toxicol. Pathol. 2009, 61:255. (IF 2.6)

210. Daneshian M, von Aulock S and HartungT. Assessment of pyrogenic contaminations with the validated human whole blood assay. Nature Protocols 2009, 12:1709-1721. (IF 8.0)

211. Eskes C, de Moura Sa-Rocha V, Nunes J, Presgrave O, de Carvalho D, Masson P, Rivera E, Coecke S, Kreysa J and HartungT. Proposal for a Brazilian centre on alternative test methods. ALTEX 2009, 26:265-268. (IF 4.1)

212. Ferrario D, Collotta A, Carfi M, Bowe G, Vahter M, HartungT and Gribaldo L. Arsenic induces telomerase expression and maintains telomere length in human cord blood cells. Toxicology 2009, 260:132-141. (IF 4.0)

213. Griesinger C, Hoffmann S, Kinsner-Ovaskainen A, Coecke S and HartungT. Proceedings of the First International Forum Towards Evidence-Based Toxicology. Conference Centre Spazio Villa Erba, Como, Italy. 15−18 October 2007. Preface. Human Exp. Toxicol. 2008, Special Issue: Evidence-Based Toxicology (EBT) 2009, 28:83-86. (IF 1.5)

214.Griesinger C, Hoffmann S, Kinsner A, Coecke S and HartungT. Current schemes for decision-making in toxicology. Human Exp. Toxicol. 2009, 28:147. (IF 1.5)

215.Griesinger C, Hoffmann S, Kinsner A, Coecke S and HartungT. Current information sources for hazard identification. Human Exp. Toxicol. 2009, 28:149. (IF 1.5)

216.Griesinger C, Hoffmann S, Kinsner A, Coecke S and HartungT. Evidence-based tools in toxicological basic research. Human Exp. Toxicol. 2009, 28:151-152. (IF 1.5)

217.Griesinger C, Hoffmann S, Kinsner A, Coecke S and HartungT. Evidence-based tools in toxicological hazard identification. Human Exp. Toxicol. 2009, 28:153. (IF 1.5)

218.Griesinger C, Hoffmann S, Kinsner A, Coecke S and HartungT. Evidence-based tools in toxicological decision-making. Human Exp. Toxicol. 2009, 28:155. (IF 1.5)

219.Griesinger C, Hoffmann S, Kinsner A, Coecke S and HartungT. Possible improvement of information sources on hazard and risk. Human Exp. Toxicol. 2009, 28:157. (IF 1.5)

220.HartungT, Blaauboer B and Leist M. Food for thought… on education in alternative methods in toxicology. ALTEX 2009, 26:255-263. (IF 4.1)

221.HartungT and Rovida C. Chemical regulators have overreached. Nature 2009, 460:1080-1081. (IF 38.6)

222.HartungT. Toxicology for the twenty-first century. Nature 2009, 460:208-212. doi:10.1038/460208a (IF 38.6)

223.HartungT. Fundamentals of an evidence-based toxicology Human Exp. Toxicol. 2009, 28:93-94. (IF 1.5)

224.HartungT. A toxicology for the 21stcentury: Mapping the road ahead. Tox. Sci. 2009, 109:18-23. (IF 4.3)

225.HartungT. Food for thought… on evidence-based toxicology. ALTEX 2009, 26:75-82. (IF 4.1)

226.HartungT. Per aspirin ad astra... ATLA - Altern Lab Anim 2009, 37, Suppl 2:45-47. (IF 1.4)

227.HartungT and Daston G. Are in vitro tests suitable for regulatory use? Tox. Sci. 2009, 111:233-237. (IF 4.3)

228.HartungT and Hoffmann S. Food for thought on…. in silico methods in toxicology. ALTEX 2009, 26:155-166. (IF 4.1)

229.HartungT. Vor- und Nachdenkliches… zu Evidenz-basierten Toxikologie. ALTEXethik 2009, 1:102-106. (IF 4.1)

230.HartungT and Hoffmann S. Vor- und Nachdenkliches… zu in silico Methoden in der Toxikologie. ALTEXethik 2009, 1:108-109. (IF 4.1)

231.HartungT, Blaauboer B and Leist M. Vor- und Nachdenkliches… zur Lehre von Alternativmethoden in der Toxikologie. ALTEXethik 2009, 1:117-120. (IF 4.1)

232.HartungT and Rovida C. That which must not, cannot be... a reply to the EChA and EDF responses to the REACH analysis of animal use and costs. ALTEX 2009, 26:307-311. (IF 4.1)

233.Hogberg H, Kinsner A, HartungT, Coecke S and Bal-Price A. Gene expression as a sensitive endpoint to evaluate cell differentiation and maturation of the developing central nervous system in primary cultures of rat cerebellar granule cells (CGCs) exposed to pesticides. Toxicol. Appl. Pharmacol. 2009, 235:268-286. (IF 4.0)

234.Kinsner-Ovaskainen A; Griesinger C, Hoffmann A, Coecke S, Bowe G, Campana C and HartungT. An online portal to evidence-based toxicology. Human Exp. Toxicol. 2009, 28:161-162. (IF 1.5)

235.Kinsner-Ovaskainen A, Bulgheroni A, HartungT and Prieto P. ECVAM’s ongoing activities in the area of acute oral toxicity. Toxicol. In Vitro 2009, 23:1535-1540. (IF 2.7)

236.Moore N, Bremer S, Carmichael N, Daston G, Dent M, Gaoua-Chapelle W, Hallmark N, HartungT, Holzum B, Hübel U, Meisters M-L, Schneider S, van Ravenzwaay B and Hennes C. A modular approach to the extended one-generation reproduction toxicity study: Outcome of an ECETOC task force and International ECETOC/ECVAM workshop. ATLA – Altern. Lab. Anim. 2009, 37:219-225. (IF 1.4)

237.Rahman O, Pfitzenmaier M, Pester O, Morath S, Cummings SP, HartungT and Sutcliffe IC. Macroamphiphilic components of thermophilic actinomycetes: identification of lipoteichoic acid in Thermobifida fusca. J. Bacteriol. 2008, 191:152-160. (IF 3.2)

238.Rovida C. and HartungT. Re-evaluation of animal numbers and costs for in vivo tests to accomplish REACH legislation requirements. ALTEX 2009, 26:187-208. (IF 4.1)

239.Rovida C. and HartungT. Neuevaluierung der erforderlichen Tierzahlen und Kosten der in vivo Tests zur Erfüllung der REACH Vorgaben für Chemikalien – ein Bericht des “transatlantic think tank for toxicology (t4)”. ALTEXethik 2009, 1:115. (IF 4.1)

240.Schindler S, von Aulock S, Daneshian M and HartungT. Development, validation and applications of the monocyte activation test for pyrogens based on human whole blood. ALTEX 2009, 26:293-305. (IF 4.1)

241.Schindler S, von Aulock S, Daneshian M and HartungT. Entwicklung, Validierung und Anwendungsbereiche des Monozyten Aktivationstests für Pyrogene auf der Basis menschlichen Vollbluts. ALTEXethik 2009, 1:122. (IF 4.1)

242.Schneider K, Schwarz M, Burkholder I, Kopp-Schneider A, Edler L, Kinsner-Ovaskainen A, HartungT and Hoffmann S. "ToxRTool", a new tool to assess the reliability of toxicological data. Toxicol. Lett. 2009, 189:138-144. (IF 3.2)

243.Schwarz M, Bremer S, Dencker L, Garthoff B, HartungT, Lazzari G, Mantovani A, Pellizzer C and Spielmann H. ReProTect: Hazard assessment of reproductive toxicity. Toxicol. Lett. 2009, 189, Suppl. 1:S37. (IF 3.2)

244.Scott L, Eskes C, Hoffmann S, Adriaens E, Alepée N, Bufo M, Clothier R, Facchini D, Faller C, Guest R, Harbell J, HartungT, Kamp H, Le Varlet B; Meloni M, McNamee P, Osborne R, Pape W, Pfannenbecker U, Prinsen M, Seaman C, Spielmann H, Stokes W, Trouba K, Van den Berghe C, van Goethem F, Vassallo M, Vinardell P and Zuang V. A proposed eye irritation testing strategy to reduce and replace in vivo studies using bottom-up and top-down approaches. Toxicol. In Vitro 2009, 24:1-9. (IF 2.7)


245.Adler S, Pellizzer C, Hareng L, HartungT and Bremer S. First steps in establishing a developmental toxicity test method based on human embryonic stem cells.Toxicol. In Vitro 2008, 22:200-211. (IF 2.7)

246.Ahr H-J, Alepee N, Breier S, Brekelmans C, Cotgreave I, Gribaldo L, Dal negro G, De Silva O, HartungT, Lacerda A, Leblanc B, Lecerf C, Linge JP, Luhimies S, Manou I, Maxwell G, Müller KK, Pape W, Redhead K, Schröder KR, Sladowski D, van der Jagt K and Vanparys P. Barriers to validation. A report by European Partnership for Alternative Approaches to animal testing (EPAA) working group 5. ATLA – Altern. Lab. Anim. 2008, 36:459-464. (IF 1.4)

247.Bottini AA, Alepee N, De Silva O, HartungT, Hendriksen C, Kuil J, Pazos P, Philips B, Rhein C, Schiffelers M-J, Stokes W, Theobald A, Vidal J-M, Van de Sandt H and Blaauboer B. Optimization of the post-validation process. The report and recommendations of ECVAM workshop 67. ATLA – Altern. Lab. Anim. 2008, 36:353-366. (IF 1.4)

248.Bucki R, Byfield FJ, Kulakowska A, McCormick ME, Drozdowski W, Namiot Z, HartungT and Janmey PA. Extracellular gelsolin binds lipoteichoic acid and modulates cellular response to proinflammatory bacterial wall components. J. Immunol. 2008, 181:4936-4944. (IF 5.5)

249.Cohen BC, Crofton KM, HartungT, Krewski D, Locke PA and Stephens ML. Toxicity testing in the 21st century: Better results, less use of animals. Environmental Forum 2008, March-April, 46-51. 

250.Corvi R, Albertini S, HartungT, Hoffmann S, Maurici D, Pfuhler S, van Benthem J, and Vanparys P. ECVAM retrospective validation of in vitro micronucleus test (MNT). Mutagenesis 2008, 23:271-283. (IF 3.5)

251.Daneshian M, Wendel A, HartungT and von Aulock S. High sensitivity pyrogen testing in water and dialysis solutions. J. Immunol. Meth. 2008, 336:64-70. (IF 2.2)

252.Draing C, Sigel S, Deininger S, Traub S, Munke R, Mayer C, Hareng L, HartungT, von Aulock S and Hermann C. Cytokine induction by Gram-positive bacteria. Immunobiol. 2008, 213:285-296. (IF 2.8)

253.Draing C, Traub S, Deininger S, Mang P, Moller HM, Manso M, Rossi F, Morath S, HartungT and von Aulock S. Polypropylene glycol is a selective binding inhibitor for LTA and other structurally related TLR2 agonists. Eur. J. Immunol. 2008, 38:797-808. (IF 5.0)

254.Deininger S, Traub S, Aichele D, Rupp T, Baris T, Moller HM, HartungT and von Aulock S Presentation of lipoteichoic acid potentiates its inflammatory activity. Immunobiol. 2008, 213:519-29.(IF 2.8)

255.Di Gioacchino M, Petrarca C, Perrone A, Farina M, Sabbioni E, HartungT, Martino S, Esposito DL, Lotti LV and Mariani-Costantini R. Autophagy as an ultrastructural marker of heavy metal toxicity in human cord blood hematopoietic stem cells. Sci. Total Environ. 2008, 392:50-58. (IF 3.3)

256.Goldberg A and HartungT. The emerging new toxicology – an opportunity for contract research. Eur. Pharmaceut. Contractor 2008, 42-46.

257.Halder M and HartungT. European Centre for the Validation of Alternative Methods (ECVAM): its role and contribution. In: EDQM/Council of Europe: Alternatives to animal testing: new approaches in the development and control of biologicals, 2008, 23-32.

258.HartungT. Towards a new toxicology – evolution or revolution? ATLA – Altern. Lab. Anim. 2008, 36:635-639. (IF 1.4)

259.HartungT. Thoughts on limitations of animal models. Parkinsonism & Related Disord. 2008, 14:S81-83. (IF 3.3)

260.HartungT. Food for thought … on animal tests. ALTEX 2008, 25:3-9. (IF 4.1)

261.HartungT. Vor und Nachdenkliches… zu Tierversuchen. ALTEX 2008, 25:10-16. (IF 4.1)

262.HartungT. Food for thought … on alternative methods for cosmetics safety testing. ALTEX 2008, 25:147-162. (IF 4.1)

263.HartungT. Vor und Nachdenkliches… zu Alternativen für die Sicherheitsprüfung von Kosmetika. ALTEX 2008, 25:163-179. (IF 4.1)

264.HartungT and Leist M. Food for thought … on the evolution of toxicology and phasing out of animal testing. ALTEX 2008, 25:91-96. (IF 4.1)

265.HartungT and Leist M. Vor und Nachdenkliches… zur Evolution der Toxikologie und dem Auslauf von Tierversuchen. ALTEX 2008, 25:97-102. (IF 4.1)

266.HartungT and Koeter H. Food for thought … on alternative methods for food safety testing. ALTEX 2008, 25:259-264. (IF 4.1)

267.HartungT and Koeter H. Vor- und Nachdenkliches … zur Sicherheitsprufung von Nahrungsmitteln. ALTEX 2008, 25:265. (IF 4.1)

268.Hasiwa M, Kylián O, HartungT and Rossi F. Removal of Immune-stimulatory Components from Surfaces by Plasma Discharges, Innate Immunity, 2008, 14: 89-97. (IF 2.7)

269.Hoffmann S, Edler L, Gardner I, Gribaldo L, HartungT, Klein C, Liebsch M, Sauerland S, Schechtman L, Stammati A and Nikolaidis E. Points of reference in validation - the report and recommendations of ECVAM Workshop. (IF 1.4)

270.Jacobs M, Bremer S, HartungT, Pazos P and Pellizzer C. ECVAM activities in the validation of alternatives for endocrine disruptor testing. Toxicol. Lett. 2008, 180, Suppl.1:106. (IF 3.3)

271.Kramer NE, Hasper HE, van den Bogaard PT, Morath S, de Kruijff B, HartungT, Smid EJ, Breukink E, Kok J and Kuipers OP. Increased D-alanylation of lipoteichoic acid and a thickened septum are main determinants in the nisin resistance mechanism of Lactococcus lactis. Microbiol. 2008, 154:1755-1762. (IF 0.7)     

272.Leist M, HartungT and Nicotera P. The dawning of a new age of toxicology. ALTEX 2008, 25:103-114.(IF 4.1)

273.Mattsson E, Heying R, van de Gevel JS, HartungT and Beekhuizen H. Staphylococcal peptidoglycan initiates an inflammatory response and procoagulant activity in human vascular endothelial cells. A comparison with highly purified lipoteichoic acid and TSST-1. FEMS Immunol. Med. Microbiol. 2008, 52:110-117. (IF 2.7)

274.Nilsen NJ, Deininger S, Nonstad U, Skjeldal F, Husebye H, Rodionov D, von Aulock S, HartungT, Lien E, Bakke O and Espevik T. Cellular trafficking of lipoteichoic acids and toll-like receptor 2 in relation to siganling; role of CD14 and CD36. J. Leukoc. Biol. 2008, 84:280-291. (IF 4.6)

275.van Vliet E, Morath S, Linge J, Rappsilber J, Eskes C, Honegger P, HartungT and Coecke S. A novel in vitro metabolomics approach for neurotoxicity testing, proof of principle for methyl mercury chloride and caffeine. Neurotox. 2008, 29:1-12. (IF 2.7)

276.Zuang V, Eskes C, Griesinger C and HartungT.ECVAM key area topical toxicity: update on activities. AATEX 2008, 14:S523-S528.


277.Bauhofer A, Plaul U, Torossian A, Koller M, Stinner B, Celik I, Sitter H, Greger B, Middeke M, Schein M, Wyatt J, Nyström P-O, HartungT, Rothmund M and Lorenz W. Perioperative prophylaxis with granulocyte colony-stimulating factor (G-CSF) in high-risk colorectal cancer patients for an improved recovery: a randomized, controlled trial. Surgery 2007, 141:501-510. (IF 3.4)

278.Basketter D, Pease C, Kasting G, Kimber I, Casati S, Cronin M, Diembeck W, Gerberick F, Hadgraft J, HartungT, Marty JP, Nikolaidis E, Patlewicz G, Roberts D, Roggen E, Rovida C and van de Sandt J. Skin sensitisation and epidermal disposition: The relevance of epidermal disposition for sensitisation hazard identification and risk assessment. The report and recommendations of ECVAM workshop 59. ATLA – Altern. Lab. Anim. 2007, 35: 137-154. (IF 1.4)

279.Borlon C, Godard P, Eskes C,HartungT, Zuang V and Toussaint O. The usefulness of toxicogenomics for predicting acute skin irritation on in vitro reconstructed human epidermis. Toxicol. 2007, 241:157-166. (IF 4.0)

280.Bottini AA, Amcoff P and HartungT. Vor- und Nachdenkliches… zur Globalisierung von Alternativmethoden. ALTEX 2007, 24:262-269. (IF 4.1)

281.Bottini AA, Amcoff P and HartungT. Food for thought… on globalization of alternative methods. ALTEX 2007, 24:255-261. (IF 4.1)

282.Bouvier d’Yvoire M, Prieto P, Blaauboer BJ, Bois FY, Boobis A, Brochot C, Coecke S, Freidig A, Gundert-Remy U, HartungT, Jacobs MN, Lavé T, Leahy DE, Lennernäs H, Loizou GD, Meek B, Pease C, Rowland M, Spendiff M, Yang J and Zeilmaker M. Physiologically-based Kinetic Modelling (PBK Modelling): Meeting the 3Rs Agenda. The Report and Recommendations of ECVAM Workshop 63. ATLA - Altern. Lab. Anim. 2007, 35: 661-671. (IF 1.4)

283. Bremer S, Pellizzer C, Hoffmann S, Seidle T and Hartung T. The development of new concepts for assessing reproductive toxicity applicable to large scale toxicological programs. Curr. Pharm. Des. 2007, 13:3047-3058. (IF 3.3)

284. Carfi M, Gennari A, Malerba I, Corsini E, Pallardy M, Pieters M, Van Loveren H, Vohr HW, HartungT and Gribaldo L. In vitro tests to evaluate immunotoxicity: a preliminary study. Toxicology 2007, 229:11-22. (IF 4.0)

285. Coecke S, Goldberg AM, Allen S, Buzanska L, Calamandrei G, Crofton K, Hareng L, HartungT, Knaut H, Honegger P, Jacobs M, Lein P, Li A, Mundy W, Owen D, Schneider S, Silbergeld E, Reum T, Trnovec T, Monnet-Tschudi F and Bal-Price A. Incorporating in vitro alternative methods for developmental neurotoxicity into international hazard and risk assessment strategies. Environ. Health Persp. 2007, 115:924-931. (IF 7.3)

286. Coecke S, Balls M, Bowe G, Davis J, Gstraunthaler G, HartungT, Hay R, Price A, Merten O-W, Stokes W, Schechtman L and Stacey G. Guidance on Good Cell Culture Practice. A Report of the Second ECVAM Task Force on Good Cell Culture Practice. In: Smith R. (ed). Cell Technology for Cell Products, Springer, Dordrecht, 313-315. DOI: 10.1007/978-1-4020-5476-1_49.

287. Deininger S, Figueroa-Perez I, Sigel S, Stadelmaier A, Schmidt RR, HartungT and von Aulock S. Definition of the cytokine inducing minimal structure of lipoteichoic acid using synthetic derivatives. Clin. Vacc. Immunol. 2007, 14:1629-1633. (IF 2.6)

288. Goldberg A and HartungT. Ersatz von Tierversuchen – nicht nur zum Tierschutz. Spektrum der Wissenschaften 2007, 60-68. 

289. HartungT. Europe goes alternative – another step done. ALTEX 2007, 24:355-356. (IF 4.1)

290. HartungT. Food for thought … on validation. ALTEX 2007, 24:67-72. (IF 4.1)

291.HartungT. Vor und Nachdenkliches… zur Validierung. ALTEX 2007, 24:73-80. (IF 4.1)

292.HartungT. Food for thought … on cell culture. ALTEX 2007, 24:143-147. (IF 4.1)

293.HartungT. Vor und Nachdenkliches… zur Zellkultur. ALTEX 2007, 24:148-152. (IF 4.1)

294.HartungT and Zuang V. Assessing the validity of alternative methods for toxicity testing. In: Zhai H, Wilhelm K-P and Maibach HI (editors). Dermatotoxicology, chapter 65, 7thedition. 2007, 569-576.

295.HartungT. Reduction and replacement – ECVAM's response to REACH. Toxicol. 2007, 231:91-92. (IF 3.2)

296.Hasiwa M, Kullmann K, von Aulock S, Klein C and HartungT. An in vitro pyrogen safety test for immune-stimulating components on surfaces. Biomaterials 2007, 28:1367-75. (IF 7.6)

297.Kim HG, Gim MG, Kim JY, Jin Hwang H, Ham MS, Lee JM, HartungT, Park JW, Han SH and Chung DK. Lipoteichoic acid from Lactobacillus plantarum elicits both the production of Interleukin-23p19 and suppression of pathogen-mediated Interleukin-10 in THP-1 cells. FEMS Immunol. Med. Microbiol. 2007, 49:205-214. (IF 2.7) 

298.Kimber I, Agius R, Basketter D, Corsini E, Cullinan P, Dearman R, Gimenez-Arnau E, Greenwell L, HartungT, Kuper F, Maestrelli P, Roggen E and Rovida C. Chemical respiratory allergy: Opportunities for hazard identification and characterisation. The report and recommendations of ECVAM workshop 60. ATLA – Altern. Lab. Anim. 2007, 35:243-265. (IF 1.4) 

299.Larmonier N, Cathelin D, Larmonier C, Nicolas A, Mérino D, Janikashvili N, Audia S, 
Bateman A, Thompson J, Kottke T, HartungT, Katsanis E, Vile R, Bonnotte B.
The inhibition of TNF-alpha anti-tumoral properties by blocking antibodies promotes tumor 
growth in a rat model. Exp. Cell Res. 2007, 313:2345-2355. (IF 3.6)

300.Liljeroos M, Vuolteenaho R, HartungT, Morath S, Hallman M and Ojaniemi M. Bruton's kinase is activated by lipoteichoic acid and mediates toll-like receptor 2 responses in macrophages. Cellul. Signal. 2007, 19:625-633. (IF 4.3)

301.Linge J and HartungT. ECVAM's approach to intellectual property rights in the validation of alternative methods. ATLA – Altern. Lab. Anim. 2007, 35:441-446. (IF 1.4)

302.Mayilyan KR, Krarup A, Soghoyan AF, HartungT and Sim RB. MBL and L-ficolin components of the complement activation lectin pathway in schizophrenia. Molecular Immunol. 2007, 44:3940. (IF 2.7)

303.Mazzotti F, Beuttler J, Zeller R, Fink U, Schindler S, Wendel A, HartungT and von Aulock S. In vitro pyrogen test – a new test method for solid medical devices. J. Biomed. Mater. Res. 2007, 80:276-282.(IF 2.8)

304.Raisanen L, Draing C, Pfitzenmaier M, Schubert K, Jaakonsaari T, von Aulock S, HartungT and Alatossava T. Molecular Interaction between LTAs and L. delbrueckii phages depends on
D-alanyl and alpha-Glucose substitution of poly(glycerophosphate) backbones. J. Bacteriol. 2007, 189:135-140. (IF 3.2)

305.Schindler S, Fennrich S, Crameri R, Jungi TW, Montag T and HartungT. Fever in the test tube – towards a human(e) pyrogen test. ALTEX 2007, 24, Special Issue:60-62. (IF 4.1)

306.Spiller S, Dreher S, Meng G, Grabiec A, Thomas W, HartungT, Pfeffer K, Hochrein H, Brade H, Bessler W, Wagner H and Kirschning CJ. Cellular Recognition of Tri-Myristoylated Peptide or Enterobacterial LPS via both TLR2 and TLR4. J. Biol. Chem. 2007, 282:13190-13198. (IF 4.7)

307.van Vliet E, Eskes C, Stingele S, Gartlon J, Price A, Farina M, Ponti J, HartungT, Sabbioni E, and Coecke S. Development of a mechanistically-based genetically engineered PC12 cell system to detect p53-mediated cytotoxicity. Toxicol. In Vitro 2007, 21:698-705. (IF 2.7)

308.van Vliet E, Stoppini L, Balestrino M, Eskes C, Griesinger C, Sobanski T, HartungT and Coecke S. Electrophysiological recording of re-aggregating brain cell cultures on multi-electrode arrays to detect acute neurotoxic effects. Neurotox. 2007, 28:1136-1146. (IF 2.7)

309.von Aulock S, HartungT and Hermann C. "Comment on 'Not Lipoteichoic Acid but Lipoproteins Appear to Be the Dominant Immunobiologically Active Compounds in Staphylococcus aureus'". J. Immunol. 2007, 178:2610. (IF 5.5)


310.Adler S, Pellizzer C, Paparella M, HartungT and Bremer S. The effects of solvents on embryonic stem cell differentiation. Toxicol. In Vitro 2006, 20:265-271. (IF 2.7)

311.Balls M, Amcoff P, Bremer S, Casati S, Coecke S, Clothier R, Combes R, Corvi R, Curren R, Eskes C, Fentem J, Gribaldo L, Halder M, HartungT, Hoffmann S, Schechtman L, Scott L, Spielmann H, Stokes W, Tice R, Wagner D and Zuang V. The Principles of Weight of Evidence Validation of Test Methods and Testing Strategies. The Report and Recommendations of ECVAM Workshop 58. ATLA – Altern. Lab. Anim. 2006, 34: 603-620. (IF 1.4)

312.Balls M, Coecke S, Bowe G, Davis J, Gstraunthaler G, HartungT, Hay R, Merten OW, Price A, Schechtman LM, Stacey G and Stokes W. The importance of good cell culture practice (GCCP). ALTEX 2006, 23 Suppl:270-273. (IF 4.1)

313.Boveri M, Kinsner A, Berezowski V, Lenfant A-M, Draing C, Cecchelli R, Dehouck M-P, HartungT, Prieto P and Bal-Price A. Highly purified lipoteichoic acid from Gram-positive bacteria induces in vitro blood-brain barrier disruption through glia activation: role of pro-inflammatory cytokines and nitric oxide. Neurosci. 2006, 137:1193-1209. (IF 3.1)

314.Coecke S, Ahr H, Blaauboer BJ, Bremer S, Casati S, Castell J, Combes R, Corvi R, Crespi CL, Cunningham ML, Elaut G, Eletti B, Freidig A, Gennari A, Ghersi-Egea J-F, Guillouzo A, HartungT, Hoet P, Ingelman-Sundberg M, Munn S, Janssens W, Ladstetter B, Leahy D, Long A, Meneguz A, Monshouwer M, Morath S, Nagelkerke F, Pelkonen O, Ponti J, Prieto P, Richert L, Sabbioni E, Schaack B, Steiling W, Testai E, Vericat J-A and Worth A. Metabolism: A bottleneck in in vitro toxicological test development. ATLA – Altern. Lab. Anim. 2006, 34:49-84. (IF 1.4)

315.Coecke S, Elaut G and HartungT. De rol van ECVAM in het validieren en implementeren van alternativen voor prorfdieren. In: Swart J, Groothuis G, Horbach J and van der Valk J. Kan het ook anders? 2006, DAMON, Budel, The Netherlands

316.Coecke S, Eskes C, Gartlon J, Kinsner A, Price A, van Vliet E, Prieto P, Boveri M, Bremer S, Adler S, Pellizzer C, Wendel A and HartungT. The value of alternative testing for neurotoxicity in the context of regulatory needs. Env. Toxicol. Pharmacol. 2006, 21:153-167(IF 2.0)

317.Corvi R, Ahr H-J, Albertini S, Blakey DH, Clerici L, Coecke S, Douglas GR, Gribaldo L, Groten JP, Haase B, Hamernik K, HartungT, Inoue T, Indans I, Maurici D, Orphanides G, Rembges D, Sansone S-A, Snape JR, Toda E, Tong W, van Delft JH, Weis B and Schechtman LM. Validation of toxicogenomics-based test systems: ECVAM-ICCVAM/NICEATM considerations for regulatory use. Environ. Health Persp. 2006, 114:420-429. (IF 7.3)

318.Daneshian M, Guenther A, Wendel A, HartungT and von Aulock S. In vitro pyrogen test for toxic or immunomodulatory drugs. J. Immunol. Meth. 2006, 313:169-175. (IF 2.2)

319.Dehus O, HartungT and Hermann C. Endotoxin evaluation of eleven lipopolysaccharides by whole blood assay does not always correlate with Limulus amebocyte lysate assay. J. Endotoxin Res. 2006, 12:71-80. (IF 2.7)

320.Draing C, Pfitzenmaier M, Zummo S, Mancuso G, Geyer A, HartungT and von Aulock S. Comparison of lipoteichoic acid from different serotypes of Streptococcus pneumoniae. J. Biol. Chem. 2006, 281:33849-33859. (IF 4.7)

321.Figueroa-Perez I, Stadelmaier A, Deininger S, Aulock S, HartungT andSchmidt RR.Synthesis of Staphylococcus aureus lipoteichoic acid derivatives for determining the minimal structural requirements for cytokine induction.Carbohydr. Res. 2006, 341:2901-11. (IF 2.0)

322.Goldberg A and HartungT. Not just for the rabbits. Scientific American 2006, 294:84-91. (IF 1.5)

323.HartungT. ECVAM's progress in implementing the 3Rs in Europe. ALTEX 2006, Suppl., 23:21-28. (IF 4.1)

324.Hattar K, Grandel U, Moeller A, Fink L, Iglhaut J, HartungT, Morath S, Seeger W, Grimminger F and Sibelius U. Lipoteichoic acid (LTA) from Staphylococcus aureus stimulates human neutrophil cytokine release by a CD14-dependent, toll-like-receptor-independent mechanism: Autocrine role of tumor necrosis factor-[alpha] in mediating LTA-induced interleukin-8 generation. Crit. Care Med. 2006, 34:835-41. (IF 6.1)

325.Hermann C, von Aulock S, Dehus O, Keller M, Okigami H, Gantner F, Wendel A, and HartungT. Endogenous cortisol determines the circadian rhythm of LPS- but not LTA-inducible cytokine release.  Eur. J. Immunol. 2006, 36:371-379. (IF 5.0)

326.Hoffmann S and HartungT. Designing validation studies more efficiently according to the modular approach: retrospective analysis of the EPISKIN test for skin corrosion. ATLA – Altern. Lab. Anim. 2006, 34:177-191. (IF 1.4)

327.Hoffmann S and HartungT. Towards an evidence-based toxicology. Human. Exp. Toxicol. 2006, 25:497-513.(IF 1.5)

328.Kinsner A, Boveri M, Hareng L, Brown GC, Coecke S, HartungT and Bal-Price A. Highly purified lipoteichoic acid induced proinflammatory signalling in primary culture of rat microglia through Toll-like receptor 2: selective potentiation of nitric oxide production by muramyl dipeptide. J. Neurochem. 2006, 99:596-607. (IF 4.0)

329.Lotz S, Starke A, Ziemann C, Morath S, HartungT, Solbach W and Laskay T. Beta-lactam antibiotic-induced release of lipoteichoic acid from Staphylococcus aureus leads to activation of neutrophil granulocytes. Ann. Clin. Microbiol. Antimicrob. 2006, 5:15. (IF 1.6)

330.Muller M, Bunk S, Diterich I, Weichel M, Rauter C, Hassler D, Hermann C, Crameri R, and HartungT. Identification of Borrelia burgdorferi ribosomal protein L25 by phage surface display and evaluation for serodiagnosis. J. Clin. Microbiol. 2006, 44:3778-3780. (IF 4.1)

331.Muller M, Stamme C, Draing C, HartungT, Seydel U and Schromm AB. Cell activation of human macrophages by lipoteichoic acids is strongly attenuated by lipopolysaccharide-binding protein. J. Biol. Chem. 2006, 42:31448-31456. (IF 4.7)

332.Palumbo E, Degrohan M, Sandrococconcelli P, Kleerbezem M, Geyer A, HartungT, Morath S and Hols P. D-Alanyl ester depletion of teichoic acids in Lactobacillus plantarum results in a major modification of lipoteichoic acid composition and cell wall perforations at the septum mediated by the Acm2 autolysin. J. Bacteriol. 2006, 188:3709-3715. (IF 3.2)

333.Prieto P, Baird AW, Blaauboer BJ, Vicente J, Ripoll C, Corvi R, Dekant W, Dietl P, Gennari A, Gribaldo L, Griffin JL, HartungT, Heindel JJ, Hoet P, Jennings P, Marocchio L, Noraberg J, Pazos P, Westmoreland C, Wolf A, Wright J and Pfaller W. The assessment of repeated dose toxicity in vitro: a proposed approach. ATLA – Altern. Lab. Anim. 2006, 34:315-341. (IF 1.4)

334.Scheel O, Papavlassopoulos M, Blunck R, Gebert A, HartungT, Zähringer U, Seydel U and Schromm A. Cell activation by ligands of the Toll-like receptor and interleukin-1 receptor family depends on the function of the large-conductance potassium channel MaxiK in human macrophages. Infect. Immun. 2006, 74:4354-4356. (IF 4.1)

335.Schindler S, Rosenberg U, Schlote D, Panse K, Kempe A, Fennrich S and HartungT. Pyrogen testing of lipidic parenterals with a novel in vitro test. PharmEuropa Sci. Notes 2006, 1-7.

336.Schindler S, Spreitzer I, Loschner, Hoffmann S, Hennes K, Halder M, Brügger P, Frey E, HartungT and Montag T. International validation of pyrogen tests based on cryopreserved human primary blood cells. J. Immunol. Meth. 2006, 316:42-51. (IF 2.2)

337.Spielmann H, Seiler A, Bremer S, Hareng L, HartungT, Ahr H, Faustman E, Haas U, Moffat GJ, Nau H, Vanparys P, Piersma A, Sintes JR and Stuart J. The practical application of three validated in vitro embryotoxicity tests. The report and recommendations of an ECVAM/ZEBET workshop (ECVAM workshop 57). ATLA – Altern. Lab. Anim. 2006, 34:527-38. (IF 1.4)

338.Stacey GN and HartungT. Availability, standardization and safety of human cells and tissues for drug screening and testing. Pp. 231-250, In: Marx U and Sandig V. Drug Testing In Vitro: Breakthroughs and Trends in Cell Culture Technology, WILEY-VCH Verlag, Weinheim 2007.

339.Stadelmaier A, Figueroa-Perez I, Deininger S, von Aulock S, HartungT and Schmidt RR. A Staphylococcus aureus lipoteichoic acid (LTA) derived structural variant with two diacylglycerol residues. Bioorg. Med. Chem. 2006, 14:6239-6254. (IF 2.9)

340.Traub S, von Aulock S, HartungT and Hermann C. MDP and other muropeptides – direct and synergistic effects on the immune system. J. Endotox. Res. 2006, 12:69-85. (IF 2.7)

341.Triantafilou M, Gamper FGJ, Haston RM, Mouratis RA, Morath S, HartungT and Triantafilou K. Membrane sorting of toll-like receptor (TLR)-2/6 and TLR2/1 heterodimers at the cell surface determines heterotypic associations with CD36 and intracellular targeting. J. Biol. Chem. 2006, 281:31002-31011. (IF 4.7)


342.Adler S, Paparella M, Pellizzer C, HartungT and Bremer S. The detection of differentiation inducing chemicals by using the green fluorescent protein expression in genetically engineered teratocarcinoma cells. ATLA – Altern. Lab. Anim. 2005, 33:91-103. (IF 1.4)

343.Bogni A, Monshouwer M, Moscone A, Hidestrand M, Ingelman-Sundberg, HartungT and Coecke S. Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles. Toxicol. In Vitro 2005, 19:621-629. (IF 2.7)

344.Boveri M, Berezowski V, Price A, Slupek S, Lenfant A-M, Benaud C, HartungT, Cecchelli R, Prieto P and Dehouk M-P. Induction of blood-brain barrier properties in cultured barin capillary endothelial cells: comparison between primary glial cells and C6 cell line. Glia 2005, 51:187-198. (IF 5.1)

345.Casati S, Aeby P, Basketter DA, Cavani A, Gennari A, Gerberick, GF, Griem P, HartungT, Kimber I, Lepoittevin J-P, Meade BJ, Pallardy M, Rougier N, Rousset F, Rubinstenn G, Sallusto F, Verheyen GR and Zuang V. Dendritic cells as a tool for the predictive identification of skin sensitisation hazard. ATLA – Altern. Lab. Anim. 2005, 33:47-62. (IF 1.4)

346.Coecke S, Balls M, Bowe G, Davis J, Gstraunthaler G, HartungT, Hay R, Merten O-W, Price A, Schechtman L, Stacey G and Stokes W. Guidance on Good Cell Culture Practice. ATLA – Altern. Lab. Anim. 2005, 33: 261-287. (IF 1.4)

347.Dalpke A, Lehner M, HartungT and Heeg K. Differential effects of CpG-DNA in TLR-2/TLR-4/TLR-9 tolerance and cross-tolerance. Immunology 2005, 116:203-212. (IF 3.7)

348.Figuero-Perez I, Stadelmaier A, Morath S, HartungT and Schmidt RR. Synthesis of structural variants of Staphylococcus aureus lipoteichoic acid (LTA). Tetrahedron 2005, 16:493-506. (IF 2.8)

349.Forestier M, Buechi L, Hermann C, HartungT and Beer JH. Fine and ultrafine particles differentially affect the PFA-100-times and raise proinflammatory cytokines in human blood. Blood 2005, 106:2640. (IF 9.1)

350.Gennari A, Ban M, Braun A, Casati S, Corsini E, Dastych J, Descotes J, HartungT, Hooghe-Peters, House R, Pallardy M, Pieters R, Reid L, Tryphonas H, Tschirhart E, Tuschl H, Vandebriel R and Gribaldo L. The use of in vitro systems for evaluating immunotoxicity: the report and recommendations of an ECVAM workshop. J. Immunotox. 2005, 2:61-83. (IF 1.6)

351.Grandel U, Hopf M, Buerke M, Hattar K, Heep M, Fink L, Bohle RM, Morath S, HartungT, Pullamsetti S, Schermuly RT, Seeger W, Grimminger F and Sibelius U. Mechanisms of cardiac depression caused by lipoteichoic acids from Staphylococcus aureus in isolated rat hearts. Circulation 2005, 112:691-698. (IF 15.2)

352.Grangette C, Nutten S, Palumbo E, Morath S, Hermann C, Dewulf J, Pot B, HartungT, Hols P and Mercenier A. Enhanced anti-inflammatory capacity of a Lactobacillus plantarum mutant synthesizing modifed teichoic acids. Proc. Natl. Acad. Sci. U S A 2005, 102:10321-10326. (IF 9.4)

353.Hareng L, Pellizzer C, Bremer S, Schwarz M and HartungT. The Integrated Project ReProTect: a novel approach in reproductive toxicity hazard assessment. Reproductive Toxicology 2005, 20:441-452.(IF 2.1)

354.Hattar K, van Burck S, Bickenbach A, Grandel U, Maus U, Lohmeyer J, Csernok E, Hartung T, Seeger W, Grimminger F and Sibelius U. Anti-proteinase 3 antibodies (c-ANCA) prime CD14-dependent leukocyte activation. J Leukoc Biol 2005, 78:992-1000. (IF 4.6)

355.Henneke P, Morath S, Uematsu S, Weichert S, Pfitzenmaier M,Takeuchi O, Mueller A, Poyart C, Akira S, Berner R, Teti G, Geyer A, HartungT, Trieu-Cuot P, Kasper DL and Golenbrock DT. Role of lipoteichoic acid in the phagocyte response to group B Streptococcus.J. Immunol. 2005, 174:6449-6455. (IF 5.5)

356.Hoebe K, Georgel P, Rutschmann S, Du X, Mudd S, Crozat K, Sovath S, Shamel L, HartungT, Zahringer U and Beutler B. CD36 is a sensor of diacylglycerols. Nature 2005, 433:523-527. (IF 38.6)

357.Hoffmann S, Cole T and Hartung T. Skin irritation: prevalence, variability, and regulatory classification of existing in vivo data from industrial chemicals. Regul. Toxicol. Pharmacol. 2005, 41:159-166.(IF 2.1)   

358.Hoffmann S and HartungT. Diagnosis: Toxic! – Trying to apply approaches of clinical diagnostics and prevalence in toxicology considerations. Toxicol. Sci. 2005, 85, 422-428. (IF 4.3)

359.Hoffmann S, Luderitz-Puchel U, Montag-Lessing U and HartungT. Optimisation of pyrogen testing in parenterals according to different pharmacopoeias by probabilistic modelling, J. Endotoxin Res. 2005, 11:25-31. (IF 2.7)

360.Hoffmann S, Peterbauer A, Schindler S, Fennrich S, Poole S. Mistry Y, Montag-Lessing T, Spreitzer I, Loschner B, vam Aalderen M, Bos R, Gommer M, Nibbeling R, Werner-Felmayer G, Loitzl P, Jungi T, Brcic M, Brugger P, Frey E, Bowe G, Casado J, Coecke S, de Lange J, Mogster B, Naess LM, Aaberge IS, Wendel A and HartungT. International validation of novel pyrogen tests based on the human fever reaction. J. Immunol. Meth. 2005, 298:161-173. (IF 2.2)

361.Kindinger I, Daneshian M, Baur H, Gabrio T, Hofmann A, Fennrich S, von Aulock S and HartungT. A new method to measure air-borne pyrogens based on human whole blood cytokine response. J. Immunol. Meth. 2005, 298:143-153. (IF 2.2)

362.Kinsner A, Pilotto V, Deininger S, Brown GC, Coecke S, HartungT and Bal-Price A. Inflammatory neurodegeneration induced by lipoteichoic acid from Staphylococcus aureus is mediated by glia activation: the role of nitrosative and oxidative stress, mitochondrial dysfunction and caspase activation. J. Neurochem. 2005, 95:1132-1143. (IF 4.0)

363.Lund S, Porzgen P, Mortensen AL, Hasseldam H, Bozyczko-Coyne, Morath S, HartungT, Bianchi M, Ghezzi P, Bsibsi M, Dijkstra S and Leist M. Inhibition of microglial inflammation by the inhibitor CEP-1347. J. Neurochem. 2005, 49:1439-1451. (IF 4.0)

364.Morath S, von Aulock A and HartungT. Structure/ function relationships of lipoteichoic acids.  J. Endotoxin Res. 2005, 11:348-356. (IF 2.7)

365.Pellizzer C, Bremer S and HartungT. Developmental toxicity testing from animal towards embryonic stem cells. ALTEX 2005, 22:47-57. (IF 4.1)

366.Rauter C, Mueller M, Diterich I, Zeller S, Hassler D, Meergans T and Hartung T. Critical evaluation of urine PCR for Lyme Borreliosis. Clin. Diagn. Lab. Immunol. 2005, 12:910-917. (IF 2.5)

367.Rauter C and HartungT. Prevalence of Borrelia burgdorferi sensu lato genospecies in Ixodes
ricinus ticks in Europe - a Metaanalysis. Appl. Environ. Microb. 2005, 71:7203-7216. (IF 3.7)

368.Rohrig CH, Retz OA, Hareng L, HartungT and Schmidt RR. A new strategy for the synthesis of dinucleotides loaded with glycosylated amino acids-investigations on in vitro non-natural amino acid mutagenesis for glycoprotein synthesis. Chembiochem. 2005, 5:1805-1816. (IF 3.7)

369.Schroder NW, Diterich I, Zinke A, Eckert J, Draing C, Baehr VV, Hassler D, Priem S, Hahn K, Michelsen KS, HartungT, Burmester GR, Gobel UB, Hermann C and Schumann RR. Heterozygous Arg753Gln polymorphism of human TLR-2 impairs immune activation by Borrelia burgdorferi and protects from late stage Lyme disease. J. Immunol. 2005, 175:2534-2540. (IF 5.5)

370.Zuang V and HartungT. Making validated alternatives available – the strategies and work of the European Centre for the Validation of Alternative Methods (ECVAM). AATEX 2005, 11:15-26.


371.von Aulock S, Boneberg E-M, Diterich I and HartungT. G-CSF (Filgrastim) treatment primes for increased ex vivo inducible prostanoid release. J. Pharmacol. Exp. Therapeut. 2004, 308:754-759. (IF 3.9)

372.von Aulock S, Schroder NWJ, Traub S, Guenzius K, Lorenz E, HartungT, Schumann R and Hermann C. No influence of hetreozygous toll-like receptor 2 polymorphism on lipoteichoic acid induced chemokine and inflammatory response. Infect. Immun. 2004, 72:1828-1831.(IF 4.1)

373.von Aulock S, Diterich I, Hareng L and HartungT. G-CSF: boosting endogenous production--a new strategy? Curr. Opin. Investig. Drugs 2004, 5:1148-52. (IF 3.6)

374.Boveri M, Pazos P, Gennari A. Casado J, HartungT and Prieto P. Comparison of the sensitivity of different toxicological endpoints in Caco-2 cells after cadmium chloride treatment. Arch. Toxicol. 2004, 78:201-206.(IF 5.2)

375.Bremer S and HartungT. The use of embryonic stem cells for regulatory developmental toxicity testing in vitro--the current status of test development. Curr. Pharm. Des. 2004, 10:2733-2747. (IF 3.3)

376.Dahle MK, Overland G, Myhre AE, Stuestol JF, HartungT, Krohn CD, Mathiesen O, Wang JE and Aasen AO. The phosphatidylinositol 3-kinase/protein kinase B signaling pathway is activated by lipoteichoic acid and plays a role in Kupffer cell production of interleukin-6 (IL-6) and IL-10. Infect. Immun. 2004, 72:5704-11. (IF 4.1)

377.Gennari A, Berghe C, Casati S, Castell J, Clemedson C, Coecke S, Colombo A, Curren R, Negro GD, Goldberg A, Gosmore C, HartungT, Langezaal I, Lessigiarska I, Maas W, Mangelsdorf I, Parchment R, Prieto P, Sintes JR, Ryan M, Schmuck G, Stitzel K, Stokes W, Vericat JA and Gribaldo L. Strategies to Replace In Vivo Acute Systemic Toxicity Testing. ATLA – Altern. Lab. Anim. 2004, 32:437-59. (IF 1.4)

378.Gruber FP and HartungT. Alternatives to animal experimentation in basic research. ALTEX 2004, 21 Suppl. 1:3-31. (IF 4.1)

379.HartungT, Bremer S, Casati S, Coecke S, Corvi R, Fortaner S, Gribaldo L, Halder M, Hoffmann S, Roi AJ, Prieto P, Sabbioni E, Scott L, Worth A and Zuang V. A Modular Approach to the ECVAM principles on test validity.  ATLA - Altern Lab Anim 2004, 32:467-472. (IF 1.4)

380.HartungT and Gribaldo L. New hepatocytes for toxicology? Trends Biotechnol. 2004, 22:613-5. (IF 9.7)

381.Hermann C, Gueinzius K, Oehme A, von Aulock S, Straube E and HartungT. Evaluation of quantitative and semi-quantitative ELISAs for immunoglobulin G against Chlamydophila pneumoniae in comparison to microimmunofluorescence test for patients with respiratory tract infections. J. Clin. Microbiol. 2004, 42:2476-2479. (IF 4.1)

382.Jennings P, Koppelstaetter C, Pfaller W, Morin JP, HartungT and Ryan MP.  Assessment of a new cell culture perfusion apparatus for in vitro chronic toxicity testing. Part 2: Toxicological evaluation. ALTEX 2004, 21:61-66. (IF 4.1)   

383.Knapp S, Hareng L, Rijneveld AW, Bresser P, van der Zee JS, Florquin S, HartungT and van der Poll T. Endogenous granulocyte colony-stimulating factor activates neutrophils but blunts pro-inflammatory cytokine response in murine pneumococcal pneumonia.J. Inf. Dis. 2004, 189:1506-1514. (IF 5.9)

384.Koppelstaetter C, Jennings P, Ryan MP, Morin JP, Hartung T and Pfaller W. Assessment of a new cell culture perfusion apparatus for in vitro chronic toxicity testing. Part 1: Technical description. ALTEX 2004, 21:51-60. (IF 4.1)     

385.Lotz S, Aga E, Wilde I, van Zandbergen G, HartungT, Solbach W and Laskay T. Highly purified lipoteichoic acid activates neutrophil granulocytes and delays their spontaneous apoptosis via CD14 and TLR2. J. Leukoc. Biol. 2004, 75:467-477. (IF 4.6)

386.Lynch NJ, Roscher S, HartungT, Morath S, Matsusshita M, Maennel DN, Kuraya M, Fujita T and Schwaeble WJ. L-ficolin specifically binds to lipoteichoic acid, a cell wall constituent of Gram-positive bacteria, and activates the lectin pathway of complement. J. Immunol. 2004, 172:1198-1202. (IF 5.5)

387.Mattsson E, HartungT, Morath S and Egesten A. Highly purified lipoteichoic acid from Staphylococcus aureus induces procoagulant activity and tissue factor expression in human monocytes but is a weak inducer in whole blood - comparison with peptidoglycan. Infect. Immun. 2004, 72:4322-4326. (IF 4.1)

388.Netea MG, Sutmuller R, Hermann C, Van der Graaf CA, Van der Meer JW, van Krieken JH, HartungT, Adema G and Kullberg BJ. Toll-like receptor 2 suppresses immunity against Candida albicans through induction of IL-10 and regulatory T cells. J. Immunol. 2004, 172:3712-3718. (IF 5.5)

389.Pellizzer C, Adler S, Corvi R, HartungT and Bremer S, Monitoring of teratogenic effects in vitro by analysing a selected gene expression pattern. Toxicol. In Vitro 2004, 18:325-335. (IF 2.7)

390.Pellizzer C, Bello E, Adler S, HartungT and Bremer S. Detection of tissue-specific effects by methotrexate on differentiating mouse embryonic stem cells. Birth Defects Res. Part B Dev. Reprod. Toxicol. 2004, 71:331-41.(IF 3.2)

391.Sabbioni E, Gatti AM and HartungT. Pathology of new diseases induced by nanoparticles and in vitro toxicology research. Pathology Int. 2004, 54 (Suppl. 1):S141-S148. (IF 1.7)

392.Schindler S, Asmus S, von Aulock S, Wendel A, HartungT and Fennrich S. Cryopreservation of human whole blood for pyrogenicity testing. J. Immunol. Meth. 2004, 294:89-100. (IF 2.4)

393.Schneider C, von Aulock S, Zedler S, Schinkel C, HartungT. and Faist E, Perioperative recombinant human granulocyte colony-stimulating factor (filgrastim) treatment prevents immunoinflammatory dysfunction associated with major surgery. Ann. Surgery 2004,239:75-81. (IF 6.3)

394.Traub S, Kubasch N, Morath S, Kresse M, HartungT, Schmidt RR and Hermann C. Structural requirements of synthetic muropeptides to synergise with LPS in cytokine induction. J. Biol. Chem. 2004, 279:8694-8700. (IF 4.7)

395.Triantafilou M, Morath S, Mackie A, HartungT and Triantafilou K. Lateral diffusion of Toll-like receptors reveals that they are transiently confined within lipid rafts on the plasma membrane. J. Cell Sci. 2004, 117:4007-4014 (IF 6.1)

396.Triantafilou M, Manukyan M, Mackie A, Morath S, HartungT, Heine H and Triantafilou K. Lipoteichoic acid and Toll-like receptor 2 internalization and targeting to the Golgi is lipid raft dependent. J. Biol. Chem. 2004, 279:40882-40889. (IF 4.7)

397.Worth AP, HartungT and Van Leeuwen CJ. The role of the European centre for the validation of alternative methods (ECVAM) in the validation of (Q)SARs. SAR QSAR Environ Res 2004, 15:345-358. (IF 1.7)

398.Worth AP, Van Leeuwen CJ andHartungT. The prospects for using (Q)SARs in a changing political environment--high expectations and a key role for the European Commission's joint research centre. SAR QSAR Environ Res 2004,15:331-343. (IF 1.7)   

399.Zeidler D, Zahringer U, Gerber I, Dubery I, HartungT, Bors W, Hutzler P and Durner J. Innate immunity in Arabidopsis thaliana: lipopolysaccharides activate nitric oxide synthase (NOS) and induce defense genes. Proc. Natl. Acad. Sci. U S A 2004, 101:15811-6. (IF 9.4)


400.von Aulock S, Hermann C, HartungT. Determination of the eicosanoid response to inflammatory stimuli in whole blood and its pharmacological modulation ex vivo. J. Immunol. Meth. 2003, 188:938-43.(IF 2.4)

401.von Aulock S, Morath S, Hareng L, Knapp S, van Kessel KP, van Strijp JA and HartungT. Lipoteichoic acid from Staphylococcus aureus is a potent stimulus for neutrophil recruitment. Immunobiol. 2003, 208:413-422. (IF 2.8)

402.von Aulock S, Schröder NWJ, Gueinzius K, Traub S, Hoffmann S, Graf K, Dimmeler S, HartungT, Schumann RR, Hermann C. Heterozygous toll-like receptor 4 polymorphism influences LPS-induced cytokine release from murine macrophages but not in human whole blood. J. Inf. Dis. 2003, 188:938-43. (IF 5.9)

403.Boneberg E. and HartungT. Febrile temperatures attenuate IL-1brelease by inhibiting proteolytic processing of the proform and influence Th1/Th2 balance favoring Th2 cytokines. J. Immunol. 2003, 171:664-8. (IF 5.5)

404.Casati S andHartung T. Dritter Report der EU zu Versuchstierzahlen liegt vor. ALTEX 2002, 20:93. (IF 4.1)

405.Deininger S, Stadelmaier A, von Aulock S, Morath S, Schmidt RR, HartungT. Definition of structural prerequisites for lipoteichoic acid inducible cytokine induction by synthetic derivatives. J. Immunol. 2003, 170:4134-4138. (IF 5.5)

406.Diterich I, Rauter C, Kirschning CJ, HartungT. Borrelia burgdorferi induced immune tolerance as a model of persistence via immunosuppression. Infect. Immun. 2003, 71:3979-87.(IF 4.1)

407.Hareng L, Meergans T, von Aulock S, Volk H-D, HartungT. Cyclic AMP increases endogenous G-CSF formation in monocytes and THP-1 macrophages despite attenuated TNFaformation. Eur. J. Immunol. 2003, 33:2287-2296. (IF 5.0)

408.HartungT, von Aulock S, Schneider C, Faist E. How to leverage an endogenous immune defense mechanism – the example of ganulocyte colony-stimulating factor. Critical Care Med. 2003, 31:S65-75. (IF 6.1)

409.HartungT, Bremer S, Casati S, Coecke S, Corvi R, Fortaner S, Gribaldo L, Halder M, Roi AJ, Prieto P, Sabbioni E, Worth A and Zuang V. ECVAM’s response to the changing political environment for alternatives: Consequences of the European Union chemicals and cosmetics policy. ATLA - Altern Lab Anim 2003, 31:473-481. (IF 1.4)

410.Hermann C, von Aulock S, Graf K, HartungT. A model of human whole blood lymphokine release for in vitro and ex vivo use. J. Immunol. Meth. 2003, 275:69-79. (IF 2.4)

411.Karzai W, Cui X, Mehlhorn B, Straube E, HartungT, Gerstenberger E, Banks SM, Natanson C, Reinhart K and Eichacker PQ. Protection with antibody to tumor necrosis factor differs with similarly lethal Escherichia coli versus Staphylococcus aureus pneumonia in rats. Anesthesiol. 2003, 99:81-89. (IF 5.2)

412.Keiss H-P, Dirsch VM, HartungT, Haffner T, Vollmar AM. Garlic (Allium sativum) modulates cytokine expression in LPS-activated human blood leading to an overall inhibitory effect on NF-kB activity. J. Nutrition 2003, 133:2171-5. (IF 4.2)

413.Kiemer AK, HartungT, Huber C, Vollmar AM. Phyllantus amarus has anti-inflammatory potential by inhibition of iNOS, COX-2, and cytokines via the NfkappaB pathway. J Hepatol 2003, 38:289-297.(IF 9.9)

414.Overland G, Morath S, Yndestad A, HartungT, Thiemermann C, Foster SJ, Smedsrod B, Mathiesen O, Aukrust P, Aasen AO and Wang JE. Lipoteichoic acid is a potent inducer of cytokine production in rat and human Kupffer cells in vitro. Surg. Infect. 2003, 4:181-191. (1.9)

415.Rauter C and HartungT. Von der Zeckenentfernung bis zur Immuntherapie – Lyme-Borreliose verhindern, erkennen und behandeln. MMW Fortschr. Med. 2003, 145:36-38.

416.Rijneveld AW, Florquin S, HartungT, Speelman P, van der Poll T. Anti-tumor necrosis factor antibody impairs the therapeutic effect of ceftriaxone in murine pneumococcal pneumonia. J. Inf. Dis. 2003, 188:282-285. (IF 5.9)

417.Schindler S, Bristow A, Cartmell T, HartungT and Fennrich S. Comparison of the reactivity of human and rabbit blood towards pyrogenic stimuli. ALTEX 2002, 20:59-63. (IF 4.1)

418.Schröder NWJ, Morath S, Alexander C, Hamann L, HartungT, Zähringer U, Göbel UB, Weber JR, Schumann RR. Lipoteichoic acid (LTA) of S. pneumoniae and S. aureus activates immune cells via toll-like receptor (TLR)-2, LPS binding protein (LBP) and CD14 while TLR-4 and MD-2 are not involved. J. Biol. Chem. 2003, 278:15587-94. (IF 4.7)

419.Schröder NWJ, Hermann C, Hamann L, Göbel UB, HartungT, Schumann RR. High frequency of polymorphism Arg753Gln of the Toll-like receptor-2 (TLR-2) gene detected by a novel allele specific PCR. J. Mol. Med. 2003, 81:368-72.(IF 4.8)

420.Stadelmaier A, Morath S, HartungT, Schmidt RR. Synthesis of the first fully active lipoteichoic acid. Angew. Chemie Int. Ed. 2003, 42:916-920. auch: Stadelmaier A, Morath S, Hartung T, Schmidt RR. Synthese der ersten aktiven Lipoteichonsäure. Angew. Chemie 2003, 115:945-949. (IF 13.7)

421.Vreugdenhil ACE, Rousseau CH, HartungT, Greve JWM, Buurman WA. Lipopolysaccharide (LPS) binding protein mediates LPS detoxification by chylomicrons; a potential defense mechanism of the intestine against bacterial toxins.J. Immunol. 2003, 170:1399-1405. (IF 5.5)

422.Weber NC, Blumenthal SB, HartungT, Vollmar AM, Kiemer AK. ANP inhibits TNF-{alpha}-induced endothelial MCP-1 expression--involvement of p38 MAPK and MKP-1. J Leukoc Biol. 2003, 74:932-941.(IF 3.3)

423.Westerholt S, Pieper A-K, Griebel M, Volk H-D, HartungT, OberhofferR. Characterization of the cytokine immune response in children who have experienced an episode of typical hemolytic-uremic syndrome. Clin. Diagn. Lab. Immunol. 2003, 10:1090-1095. (IF 2.5)


424.von Aulock S and HartungT. Potential for immune reconstitution by G-CSF treatment in HIV patients. Archiv. Immunol. Ther. Exp. (AITE) 2002, 50:111-120. (IF 2.4)

425.Boneberg E and HartungT. Mechanisms of attenuated cytokine release by G-CSF. Eur. J. Immunol. 2002, 32:1717-1725. (IF 5.0)

426.Boneberg E-M and HartungT. Molecular aspects of anti-inflammatory action of G-CSF. Inflamm. Res., 2002, 51:119-128. (IF 2.0)

427.Dalpke AH, Frey M, Morath S,HartungT, Heeg K. Interaction of lipoteichoic acid and CpG-DNA during activation of innate immune cells. Immunobiol. 2002, 206:392-407. (IF 2.8)

428.Dörge H, Neumann T, Belosjorow S, Schulz R, van de Sand A, Konietzka I, HartungT, Heusch G. Coronary microembolization: the role of TNF-ain contractile dysfunction. J. Mol. Cell. Cardiol. 2002, 34:51-62. (IF 5.2)

429.Ellingsen EA, Morath S, Flo TH, Schromm A, HartungT, Thiemermann C, Espevik T, Golenbrock DT, Foster SJ, Solberg R, Aaasen AO and Wang JE. Induction of cytokine production in human T-cells and monocytes by highly-purified lipoteichoic acid: involvement of toll-like receptors and CD14. Med. Sci. Monit. 2002, 8:149-156. (IF 1.4)

430.Gstraunthaler G and HartungT. Good Cell Culture Practice (GCCP) - Good laboratory practice in the cell culture laboratory for the standardization and quality assurance of in vitro studies. In: Lehr C.M. ‘In vitro test systems for drug absorption and delivery’ Harwood Academic Publishers, Reading U.K. 2002, 112-120.

431.Hareng L and HartungT. Induction and regulation of endogenous granulocyte colony-stimulating factor formation. Biol. Chem. 2002, 383:1501-1517 (IF 2.7)

432.HartungT. Three Rs Potential in the Development and Quality Control of Pharmaceuticals, ALTEX 2002, 18 (Suppl. 1):3-11. (IF 4.1)

433.HartungT, Balls M, Bardouille C, Blanck O, Coecke S, Gstraunthaler G and Lewis D. Report of ECVAM task force on good cell culture practice (GCCP). ATLA - Altern. Lab. Anim. 2002, 30: 407-414. (IF 1.4)

434.HartungT. Comparison and validation of novel pyrogen tests based on the human fever reaction. ATLA – Altern. Lab. Anim. 2002, 30 (Suppl. 2):49-51. (IF 1.4)

435.HartungT. Vollbluttest. In: Krüger, M. Endotoxine – Bedeutung für Tiere und Menschen. Leipziger Universitätsverlag 2002, 59-72.

436.Hermann C, Spreitzer I, Schröder NWJ, Morath S, Lehner MD, Fischer W, Schütt C, Schumann RR and HartungT, Cytokine induction by purified lipoteichoic acids from various bacterial species – role of LBP, sCD14, CD14 and failure to induce interleukin-12 and subsequent interferon-grelease, Eur. J. Immunol. 2002, 32:541-551. (IF 5.0)

437.Hermann C, Graf K, Groh A, Straube E and HartungT. Comparison of eleven commercial tests for IgG sero-diagnosis of previous or persistent Chlamydia pneumoniae infection. J. Clin. Microbiol. 2002, 40:1603-1609. (IF 4.1)

438.Hoffmann S, HartungT and Beran J. Comments on the use of bootstrap resampling to assess the uncertainty of Cooper statistics. ATLA – Altern. Lab. Animal. 2002, 30:551-554. (IF 1.4)

439.Jacinto R, HartungT, McCall C and Li L. Lipopolysaccharide and lipoteichoic acid-induced tolerance and cross-tolerance: distinct alterations in IL-1 receptor-associated kinase. J. Immunol. 2002, 168:6136-6146. (IF 5.5)

440.Kiemer AK, Lehner MD, HartungT and Vollmar AM). Inhibition of Cyclooxygenase-2 by natriuretic peptides. Endocrinol. 2002, 143:846-852.(IF 4.7)

441.Kindinger I, Fennrich S, Zucker B, Linsel G and HartungT. Determination of air-borne pyrogens by the in vitro pyrogen test (IPT) based on human whole blood cytokine response. VDI Bericht 1656, 2002, 499-507.

442.Langezaal I, Hoffmann S, HartungT and Coecke S. Evaluation and prevalidation of an immunotoxicity test based on human whole blood cytokine release. ATLA – Altern. Lab. Anim. 2002, 30:581-595. (IF 1.4)

443.Lehner MD and HartungT. Endotoxin tolerance – mechanisms and beneficial effects in bacterial infection. Rev. Physiol. Biochem. Pharmacol. 2002, 144:95-141. (IF 6.3)

444.Lehner M, Schwoebel F, Kotyarov A, Leist M, Gaestel M and HartungT. Mitogen-activated protein kinase-activated protein kinase 2-deficient mice show increased susceptibility to Listeria monocytogenes infection. J. Immunol. 2002, 168:4667-4673.(IF 5.5)

445.Lorenz E, Patel DD, HartungT and Schwarz DA. A TLR4-deficient murine macrophage cell line as an in vitro assay to show TLR-4-independent signalling of B. fragilis LPS. Infect. Immun. 2002, 70:4892-4896.(IF 4.1)

446.Morath S, Geyer A, Spreitzer I, Hermann C and HartungT. Structural decomposition and heterogeneity of commercial lipoteichoic acid preparation. Infect. Immun. 2002, 70:938-944.(IF 4.1)

447.Morath S, Stadelmaier A, Geyer A, Schmidt RR and HartungT. Synthetic lipoteichoic acid from Staphylococcus aureus is a potent stimulus of cytokine release. J. Exp. Med. 2002, 195:1635-1640. (IF 14.5)

448.Rauter C, Oehme R, Diterich I, Engele M and HartungT. Distribution of clinically relevant Borrelia genospecies in ticks assessed by a novel single-run real-time PCR, J. Clin. Microbiol. 2002, 40: 36-43. (IF 4.1)

449.Schindler S, HartungT and the Human(e) Pyrogen Test Study Group. Comparison and validation of novel pyrogen tests based on the human fever reaction. Dev. Biol. Stand. 2002, 111:181-6. (IF 5.6)

450.Yipp BG, Andonegui G, Howlett CJ, Robbins SM, HartungT Ho M and Kubes P. Profound differences in leukocyte-endothelial cell responses to lipopolysaccharide versus lipoteichoic acid. J. Immunol. 2002, 168:4650-4658. (IF 5.5)


451.Boneberg E-M and HartungT. Mistletoe lectin-1 increases TNF-arelease in lipopolysaccharide stimulated whole blood via inhibition of IL-10 production. J. Pharmacol. Exp. Therapeut. 2001, 298:996-1000. (IF 3.9)

452.Coecke S, Bogni A, Langezaal I, Worth A, HartungT and Monshouwer M. The use of genetically engineered cells for assessing CYP2D6-related polymorphic effects, Toxicol. In Vitro 2001, 15:553-556. (IF 2.7)

453.Diterich I, Härter L, Hassler D, Wendel A and HartungT, Modulation of cytokine release in ex vivo stimulated blood from borreliosis patients. Infect. Immun. 2001, 69:687-694. (IF 4.1)

454.Diterich I and HartungT. Borellia burgdorferi s.l., the infectious agent of lyme borreliosis. in: Mühldorfer I and Schäfer KP. Contrib. Microbiol. 2001, 8:72-89.

455.Diterich I and HartungT. Borellia burgdorferi s.l., the infectious agent of lyme borreliosis. in: Mühldorfer I and Schäfer KP. Emerging pathogenes. Karger, Basel, 2001, 72-89.

456.Feterowski C, Weighardt H, Emmanuilidis K, HartungT and Holzmann B. Immune protection against septic peritonitis in endotoxin-primed mice is related to reduced neutrophil apoptosis. Eur. J. Immunol. 2001, 31:1268-1277. (IF 5.0)

457.Fennrich S, Zucker B und HartungT. Beispiel eines Einsatzbereiches des humanen Vollbluttests: Entwicklung eines Messverfahrens zur Abschätzung der gesundheitlichen Gefährdung durch luftgetragene mikrobielle Verunreinigungen. ALTEX 2001, 18:41-46. (IF 4.1)

458.Fischer M, Keller-Stanislawski B, Schober-Bendixen S, Schosser R, Hacke K, HartungT, Montag T. Einfluß des Konservierungsmittels Thimerosal auf die Interleukin-1 Beta Ausschüttung humaner peripherer Blutzellen. ALTEX 2001, 18:47-49. (IF 4.1)

459.Götz A, Böttcher A, Orsó E, Kapinsky M, Nagy P, Bodnár A, Spreitzer I, Liebisch G, Drobnik W, Gempel K, Horn M, Holmer S, HartungT, Multhoff G, Schütz G, Schindler H, Ulmer AJ, Heine H, Stelter F, Schütt C, Rothe G, Szöllösi J, Damjanovich S and SchmitzG, Lipopolysaccharide and ceramide docking to CD14 provokes ligand specific raft domain clustering. Eur. J. Immunol. 2001, 31: 3153-3164. (IF 5.0)

460.HartungT, Aaberge I, Berthold S, Carlin G, Charton E, Coecke S, Fennrich S, Fischer M, Gommer M, Halder M, Haslov K, Jahnke M, Monatg-Lessing T, Poole S, Schechtman L, Wendel A and Werner-Felmayer G. ECVAM workshop on novel pyrogen tests based on the human fever reaction. ATLA – Altern. Lab. Anim. 2001, 29:99-123. (IF 1.4)

461.HartungT, Gstraunthaler G, Coecke S, Lewis D, Blanck O und Balls M. Good Cell Culture Practice (GCCP) – eine Initiative zur Standardisierung und Qualitätssicherung von in vitro Arbeiten. Die Etablierung einer ECVAM Task Force on GCCP. ALTEX 2001, 18:75-78. (IF 4.1)

462.HartungT. Summary: EU standards measurements and testing project PL95-3407. Development of standardised in vitro methodology for hepatic and renal toxicity testing. ATLA – Altern. Lab. Anim. 2001, 29:493-495.(IF 1.4)

463.HartungT, Gaviria M, Garrido SM, Root RK. G-CSF and GM-CSF. in: Holland SM. Cytokine therapeutics in infectious diseases. Lippincott Wiiliams & Wilkins, 2001, 185-219.

464.Langezaal I, Coecke S. and HartungT. Whole blood cytokine response as a measure of immunotoxicity. Toxicol. In Vitro 2001, 15:313-318. (IF 2.7)

465.Lehner MD, Ittner J Bundschuh DS, von Rooijen N, Wendel A and HartungT. Improved innate immunity of endotoxin tolerant mice increases resistance to Salmonella typhimurium infection despite attenuated cytokine response. Infect. Immun. 2001, 69:463-471. (IF 4.1)

466.Lehner MD, Morath S, Michelsen KS, Schumann RR and HartungT. Induction of cross-tolerance by LPS and highly purified lipoteichoic acid via different Toll like receptors independent of paracrine mediators. J. Immunol. 2001, 165:5161-5167. (IF 5.5)

467.Morath S, Geyer A, HartungT. Structure/function-relationship of cytokine induction by lipoteichoic acid from Staphylococcus aureus. J. Exp. Med., 2001, 193:393-397. (IF 13.2)

468.Michelsen KS, Aicher A, Mohaupt M, HartungT, Dimmeler S, Kirschning CJ and Schumann RR. The role of Toll-like receptors (TLRs) in bacteria-induced maturation of murine dendritic cells -PGN and LTA are inducers of DC maturation and require TLR2. J. Biol. Chem. 2001, 276: 22041-22047. (IF 4.7)

469.Opitz B, Schröder NWJ, Spreitzer I, Michelsen KS, Kirschning CJ, Hallatschek W, Zähringer U, HartungT, Göbel UB and Schumann RR. Toll-like receptor (TLR)-2 mediates treponema glycolipid and lipoteichoic acid (LTA)-induced NF-kappa B translocation. J. Biol. Chem. 2001, 276:22041-22047. (IF 4.7)

470.Pfaller W, Balls M, Clothier R, Coecke S, Dierickx P, Ekwall B, Hanley BA, HartungT, Prieto MP, Ryan MP, Schmuck G, Sladowsky D, Vericat J-A, Wendel A, Wolf A and Zimmer J. Novel advanced in vitro methods for long-term toxicity testing – ECVAM workshop report. ATLA – Altern. Lab. Animal. 2001, 29:393-426. (IF 1.4)

471.Schneider M and HartungT. Induction of the chemokines IL-8 and MCP-1 in human whole blood by a cell-lysate of human fibroblast cells. Immunol. Lett. 2001, 75:163-165. (IF 2.3)

472.Sommer C, Lindenlaub T, Teuteberg P, Schafers M, HartungT and Toyka KV. Anti-TNF-neutralizing antibodies reduce pain-related behavior in two different mouse models of painful mononeuropathy. Brain. Res. 2001, 913:86-89. (IF 2.9)

473.van de Wetering JK, van Eijk M, van Golde LMG, HartungT, van Strijp JAG and Batenburg JJ, Characteristics of surfactant protein A and D binding to lipoteichoic acid and peptidoglycan, two major cell wall components of Gram-positive bacteria. J. Inf. Dis. 2001, 184:1143-1151. (IF 5.9)

474.Weishaupt A, Brück W, HartungT, Toyka KV and Gold R. Schwann cell apoptosis in experimental autoimmune neuritis of the Lewis rat and the functional role of tumor necrosis factor-a. Neuroscience Lett. 2001, 306: 77-80. (IF 2.0)

475.Weiss M, Fischer G, Barth E, Boneberg EM, Schneider EM, Georgieff M and HartungT. Dissociation of LPS-induced monocytic ex-vivo production of granulocyte colony-stimulating factor (G-CSF) and TNF-ain patients with septic shock. Cytokine 2001, 13:51-54. (IF 2.5)

476.Wendel A, Ryan MP, HartungT, Bach PH, Pfaller W, Morin JP, Villa P, Witkamp R, Van Gompel J and Kilty CG. Summary: EU Standards Measurements and Testing Project PL95–3407. Development of a standardised in vitro methodology for hepatic and renal toxicity testing. ATLA – Altern. Lab. Animal. 2001, 29:493-495. (IF 1.4)


477.Al-Qaoud KM, Pearlman E, HartungT, Klukowski J, Fleischer B and Hoerauf A. A new mechanism for IL-5 dependent helminth control: neutrophil accumulation and neutrophil-mediated worm encapsulation in murine filariasis are abolished in the absence of IL-5. Int. Immunol. 2000, 12:899-908. (IF 3.1)

478.Boneberg EM, Gantner F, Hareng L, Wendel A and HartungT. Human monocytes express functional receptors for granulocyte colony-stimulating factor. Blood 2000, 95:270-276. (IF 9.1)

479.Bonenberger J, Diekmann W, Fennrich S, Fischer M, Friedrich A, Hansper M, HartungT, Jahnke M, Löwer J, Montag T, Petri E, Sonntag H-G., Weigand M, Wendel A und Zucker B. Pyrogentestung mit Vollblut - Zusammenfassung eines Status-Workshops am Paul-Ehrlich-Institut, Langen, am 22.11.99. Bundesgesundheitsbl. Gesundheitsforsch. Gesundheitsschutz 2000, 43:525-533.

480.Fischer M, Hartzsch K,HartungT, und Montag-Lessing T. Prävalidierung des Vollblutpyrogentests für biologische Arzneimittel – aktuelle Ergebnisse. in: Schöffl H et al. Forschung ohne Tierversuche 2000. Springer, Wien 2000, 135-146.

481.HartungT, von Aulock S, Freitag M, Höxtermann S, Stücker M, Hoffmann K, Altmeyer P, Kottke A and Wendel A. Blood cytokine response of low dose Molgramostim (rhGM-CSF) treated patients. Cytokine, 2000, 12:1570-1574. (IF 2.5)

482.Hartung T. Chip, Chip, Hurra! Die Amerikaner feiern den Gen-Chip – feiern wir mit? ALTEX 2000, 17:101-102. (IF 4.1)

483.HartungT, von Aulock S and Wendel A. Growth factors G-CSF and GM-CSF: clinical options. In: Baue A, Faist E and Fry DE. ‘SIRS, MODS and MOF – Systemic Inflammatory Response Syndrome, Multiple Organ Dysfunction Syndrome and Multiple Organ Failure – Pathophysiology, Prevention and Therapy‘, Berlin-Heidelberg-New York, Springer 2000, 621-629.

484.HartungT, Sauer A und Wendel A. Prävalidierung eines Zellkulturmodelles für das Leberversagen im Septischen Schock. in: Schöffl H et al. Forschung ohne Tierversuche 2000. Springer, Wien 2000, 316-322.

485.Hartung T and Gstraunthaler G. The standardisation of cell culture procedures. In: Balls M, van Zeller A-M and ME Halder. Progress in the reduction, refinement and replacement of animal experimentation, Elsevier 2000, 1655-1658.

486.Hartung T, Fennrich S, Fischer M, Montag-Lessing T and Wendel A. Prevalidation of an alternative to the rabbit pyrogen test based on human whole blood. In: Balls M, van Zeller A-M and Halder ME. Progress in the reduction, refinement and replacement of animal experimentation, Elsevier 2000, 991-999.

487.Kiemer AK, HartungT and Vollmar AM. cGMP-mediated inhibition of TNF-aproduction by the atrial natriuretic peptide in murine macrophages. J. Immunol. 2000, 165:175-181. (IF 5.5)

488.Lindenlaub T, Teuteberg P, HartungT and Sommer C. Effects of neutralizing antibodies to TNF-alpha on pain reelated behaviour and nerve regeneration in mice with chronic constriction injury. Brain Res. 2000, 866:15-22. (IF 2.9)

489.Von Aulock S, Boneberg EM and HartungT. Intermittent G-CSF (Filgrastim) treatment cannot induce lymphocytosis in volunteers. Clin. Pharmacol. Therap. 2000, 68, 104. (IF 7.0)

490.Weishaupt A, Gold R, HartungT, Gaupp S, Wendel A, Brueck W and v. Toyka K. Role of TNF-alpha in high-dose antigen therapy in experimental autoimmune neuritis: inhibition of TNF-alpha by neutralizing antibodies reduces T-cell apoptosis and prevents liver necrosis. J. Neuropathol. Exp. Neurol. 2000, 59:368-376. (IF 4.6)

491.Weishaupt A, Jander S, Brück W, Kuhlmann T, Stienekemeier M, HartungT, Toyka KV, Stoll G and Gold R. Molecular mechanisms of high-dose antigen therapy in experimental autoimmune encephalomyelitis: rapid induction of Th1 type cytokines and iNOS. J. Immunol. 2000, 165:7157-7163. (IF 5.5)

492.Weiss M, Fischer G, Barth E, Boneberg E, Schneider EM, Georgieff M and HartungT. Patterns of LPS-induced ex-vivo production of granulocyte colony-stimulating factor (G-CSF) differ from those of TNF-ain patients with septic shock. Shock 2000, 13 (Suppl):104-105. (IF 2.9)

493.Westerholt S, Tollens M, Güstrau A, Oberhoffer M, Karch H, HartungT, Klare B, Pfeffer K, Emmrich P and Oberhoffer R. Inflammatory and immunological parameters in children with hemolytic uremic syndrome (HUS) and gastroenteritis – pathophysiological and diagnostic clues. Cytokine 2000, 6:822-827. (IF 3.1)


494.Ertel W, Keel M, Buergi U, HartungT, Imhof H and Trentz O. Granulocyte colony-stimulating factor inhibits neutrophil apoptosis at the local site after severe head and thoracic injury. J. Trauma 1999, 46:784-793. (IF 2.6)

495.Fan X, Stelter F, Menzel R, Jack R, Spreitzer I, HartungT and Schuett C. Structures in Bacillus subtilis are recognized by CD14 in a LBP-dependent reaction. Infect. Immun. 1999, 67:2964-2968. (IF 4.1)

496.Fennrich S, Fischer M, HartungT, Lexa P, Montag-Lessing T, Sonntag H-G, Weigandt M und Wendel A. Detection of endotoxins and other pyrogens using human whole blood. Dev. Biol. Standards, 1999, 101:131-139. (IF 5.6)

497.Fennrich S, Wendel A and HartungT. New applications of the human whole blood pyrogen assay (PyroCheck). ALTEX 1999, 16:146-149. (IF 4.1)

498.Fennrich S, Berthold S, Weigand M, Lexa P, Sonntag H-G, HartungT and Wendel A. Pyrogentestung mit humanem Blut. Der Tierschutzbeauftragte 1999, 8:102-107.

499.Gstraunthaler G and HartungT. Bologna declaration toward Good Cell Culture Practice. ATLA –Altern. Lab. Anim. 1999, 27:206. (IF 1.4)

500.HartungT, Döcke W-D, Bundschuh DS, Foote M, Gantner F, Hermann S, Lenz A, Milwee S, Rich B, Simon B, Volk H-D, von Aulock S and Wendel A. Effect of Filgrastim treatment on inflammatory cytokines and lymphocyte functions. Clin. Pharmacol. Therap. 1999, 66:415-424. (IF 6.9)

501.HartungT. Granulocyte colony-stimulating factor: its potential role in infectious disease. AIDS 1999, 13:S3-9. (IF 6.4)

502.HartungT. Anti-inflammatory aspects of Filgrastim and impact on IL-2 release. J. Hematother. Stem Cell Res. 1999, 8:S21-22. (IF 4.2)

503.Oberhoffer M, Vogelsang H, Russwurm S, HartungT and Reinhart, K. Outcome prediction by traditional and new markers of inflammation in patients with sepsis. Clin. Chem. Lab. Med. 1999, 37:363-368. (IF 3.0)

504.Stamme C, Bundschuh DS, HartungT, Gebert U, Wollin L, Nüsing R, Wendel A and Uhlig S. Temporal sequence of pulmonary and systemic inflammatory responses to graded polymicrobial peritonitis in mice. Infect. Immun. 1999, 67:5642-5650. (IF 4.1)


505.Fennrich S, Fischer M, HartungT, Lexa P, Montag-Lessing T, Sonntag H-G, Weigandt M und Wendel A. Entwicklung und Evaluierung eines Pyrogentests mit menschlichem Blut. ALTEX 1998, 15:123-128. (IF 4.1)

506.Fischer M, Hartzsch K, HartungT and Montag-Lessing T. Erste Erfahrungen bei der Prävalidierung des Vollblutpyrogentests für biologische Arzneimittel [First Results in the prevaluation of the human whole blood assay for pyrogens in biological pharmaceuticals]. ALTEX 1998, 15, Suppl. 1:10–13. (IF 4.1)

507.HartungT, Pitrak DL, Foote M, Shatzen EM, Verral SC and Wendel A. Filgrastim (r-metHuG-CSF) restores IL-2 production of blood from advanced HIV patients. J. Inf. Dis. 1998, 178:686-692.(IF 5.9)

508.HartungT. Anti-inflammatory effects of G-CSF. Curr. Opin. Hematol. 1998, 5:221-225. (IF 4.1)

509.HartungT. Immunomodulation by colony-stimulating factors, Rev. Physiol. Biochem. Pharmacol. 1998, 136:1-164. (IF 6.3)

510.HartungT und Wendel A. Ersatz von Tierversuchen in der Pharmakologie - Ziel oder Zwang, Utopie oder Realität? ALTEX 1998, 15:213-215. (IF 4.1)

511.HartungT, von Aulock S and Wendel A. Role of granulocyte colony-stimulating factor (G-CSF) in infection and inflammation. Med. Microbiol. Immunol. 1998, 187:61-69. (IF 3.6)

512.HartungT and Wendel A. Immunomodulatory properties of Filgrastim (r-metHuG-CSF) in preclinical models. in: Morstyn G et al. Filgrastim (r-metHuG-CSF) in clinical practice. Marcel Dekker, New York 1998, 397-427.

513.Hartung T. und Wendel A. Der Nachweis von Pyrogenen mit menschlichem Blut. Tierlaboratorium 1998, 20:9-16.

514.Hartung T, Crameri R and Wendel A. Entwicklung eines Pyrogentests mit Kaninchenblut [Development of a pyrogen test based on rabbit blood].ALTEX 1998, 15, Suppl. 1:17–18. (IF 4.1)

515.Senaldi G, Shaklee CL, Simon B, Rowan CG, Lacey DL andHartung T. Keratinocyte growth factor protects murine hepatocytes from tumor necrosis factor-induced apoptosis in vivo and in vitro. Hepatology 1998, 27:1584-1591. (IF 12.0)

516.Stelter F, Witt S, Fürll B, Jack RS, HartungT and Schütt C. Different efficacy of soluble CD14 treatment in high- and low-dose LPS models. Eur. J. Clin. Invest. 1998, 28:205-213. (IF 3.4)


517.Bundschuh DS, Barsig J, Hartung T, Randow F, Döcke W-D, Volk H-D and Wendel A. Granulocyte-macrophage colony-stimulating factor and IFN-grestore the systemic TNF-aresponse to endotoxin in lipopolysaccharide-desensitized mice. J. Immunol. 1997, 158:2862-2871. (IF 5.5)

518.HartungT, Sauer A, Hermann C, Brockhaus F and Wendel A. Overactivation of the immune system by translocated bacteria and bacterial products. Scand. J. Gastroenterol. 1997, 32:S98-S99. (IF 2.2)

519.HartungT and Wendel A. The detection of pyrogens with a method involving human whole blood. in: van Zutphen LFM, Balls M: Animal alternatives, welfare and ethics. Elsevier, 1997, 683-686. 

520.HartungT, Sauer A and Wendel A. A cell culture model of endotoxic shock. in: van Zutphen LFM, Balls M: Animal alternatives, welfare and ethics. Elsevier, 1997, 677-681. 

521.Keel M, Ungethüm U, Steckholzer U, Niederer E, HartungT, Trentz O, and Ertel W. Interleukin-10 counterregulates proinflammatory cytokine-induced inhibition of neutrophil apoptosis during severe sepsis. Blood 1997, 90:3356-3363. (IF 9.1)

522.Randow F, Döcke W-D, Bundschuh DS, HartungT, Wendel A and Volk H-D. In vitro prevention and reversal of lipopolysaccharide desensitization by IFNg, IL-12 and granulocyte-macrophage colony-stimulating factor. J. Immunol. 1997, 158:2911-2918. (IF 5.5)

523.Vollmar B, Messner S, Wanner GA, HartungT and Menger MD. Immunomodulatory action of granulocyte-colony-stimulating factor in a rat model of endotoxin-induced liver injury: a intravital microscopic analysis of Kupffer cell and leukocyte response. J. Leukoc. Biol. 1997, 62:710-718. (IF 3.3)


524.Barsig J, Bundschuh DS, HartungT, Bauhofer A, Sauer A and Wendel A. Control of fecal peritoneal infection in mice by colony-stimulating factors. J. Infect. Dis. 1996, 174:790-799. (IF 5.9)

525.Gebhardt R, Hartung T. Cokulturen in der in vitro-Toxikologie. Biospektrum 1996, 2:36-39.

526.HartungT, Sauer A and Wendel A. Testing of immunomodulatory properties in vitro. Dev. Biol. Stand. 1996, 86:85-96. (IF 5.6)

527.HartungT, Hermening S, Sauer A und Wendel A. Freisetzung eines Botenstoffes der Entzündung (TNF-a) aus Lebermakrophagen in Perfusions-Zellkultur. ALTEX 1996, 13:17-23. (IF 4.1)

528.HartungT and Wendel A. Detection of pyrogens using human whole blood. In Vitro Toxicol. 1996, 9:353-359. (IF 0.8)

529.HartungT, Krieger G, Volk H-D and Wendel A. Reduced proinflammatory cytokines and increased antagonists in LPS-stimulated blood from G-CSF treated volunteers. in: Faist et al. Immune consequences of trauma, shock and sepsis. Vol.II.2, Pabst, Lengerich 1996, 838-841.

530.HartungT und Wendel A. Eine Methode unter Verwendung von menschlichem Vollblut zum Ersatz des Pyrogentests am Kaninchen. in: Schöffl H et al. Forschung ohne Tierversuche 1996. Springer, Wien 1996, 34-39. 

531.Sauer A, HartungT, Aigner J and Wendel A. Endotoxin-inducible granulocyte-mediated hepatocytotoxicity requires adhesion and serine protease release. J. Leukoc. Biol. 1996, 60:633-643. (IF 4.4)

532.Sauer A,Hartung T und Wendel A. Ein in vitro-Modell zur immunpharmakologischen Untersuchung von Mechanismen der Gram-positiven und Gram-negativen Sepsis. in: Schöffl H et al. Forschung ohne Tierversuche 1996. Springer, Wien 1996, 29-33.


533.Hartung T, Döcke W-D, Gantner F, Krieger G, Sauer A, Stevens P, Volk H-D and Wendel A. Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. Blood 1995, 85:2482-2489. (IF 9.1)

534.Hartung T, Volk H-D and Wendel A. G-CSF - an anti-inflammatory cytokine. J. Endotoxin Res. 1995, 2:195-201. (IF 2.7)

535.HartungT und Wendel A. Die Erfassung von Pyrogenen in einem humanen Vollblutmodell. ALTEX 1995,12:70-75. (IF 4.1)

536.HartungT und Spielmann H. Der lange Weg zur validierten Ersatzmethode. ALTEX 1995, 12:98-103. (IF 4.1)

537.HartungT, Sauer A and Wendel A. Immunopharmacological testing in vitro. Cell Physiol. Biochem. 1995, 5:62. (IF 3.4) 

538.HartungT, Odenthal KP, Sauer A, Schwarz T und Wendel A. Entwicklung eines Verfahrens zum pharmakologischen Screening von Wirksubstanzen gegen Septischen Schock im Zellkultursystem. in: Schöffl H et al. Forschung ohne Tierversuche 1995. Springer, Wien 1995, 138-145.

539.Sauer A, HartungT, Bohlinger I, Klesen C, Helpap B und Wendel A. Histopathologie der Endotoxin-induzierten, TNF-vermittelten Leberschädigung in der Maus. Verh. Dtsch. Ges. Path. 1995, 79:300.

540.Sauer A, Hartung T und Wendel A. Die septische Leberschädigung im Zellmodell: Überaktivierung von Zellen der unspezifischen Immunabwehr. in: Schöffl H et al. Forschung ohne Tierversuche 1995. Springer, Wien 1995, 296-300.


541.HartungT und Wendel A. Entwicklung eines Zellkulturmodelles für das Organversagen im septischen Schock. ALTEX 1993, 18:6-24. (IF 4.1)

542.HartungT and Wendel A. An in vitro model of hepatic failure in septic shock. in: Faist E et al. ‘Host defense dysfunction in trauma, shock and sepsis’, Springer, Berlin 1993, 493-498. 

543.HartungT und Wendel A. Ein Zellkulturmodell für das Organversagen im septischen Schock. in: Schöffl H et al. ‘Alternativen zu Tierversuchen in Ausbildung, Qualitätskontrolle und Herz-Kreislauf-Forschung’ Springer, Wien 1993, 219-225.


544.Görgen I, HartungT, Leist M, Niehörster M, Tiegs G, Uhlig S, Weitzel F and Wendel A. Granulocyte colony-stimulating factor treatment protects rodents against lipopolysaccharide-induced toxicity via suppression of systemic tumor necrosis factor-a. J. Immunol. 1992, 149:918-924. (IF 5.5)

545.Hartung T and Wendel A. Endotoxin-inducible cytotoxicity in liver cell cultures - II: Demonstration of endotoxin-tolerance. Biochem. Pharmacol. 1992, 43:191-196. (IF 4.6)

546.HartungT, Tiegs G and Wendel A. The role of leukotriene D4in septic shock models. Eicosanoids 1992, 5:S42-S44. (IF 0.7)


547.Hartung T and Wendel A. Endotoxin-inducible cytotoxicity in liver cell cultures - I. Biochem. Pharmacol. 1991, 42:1129-1135. (IF 4.6)

548.HartungT, Leist M, Tiegs G, Baschong W and Wendel A. Solcoseryl prevents inflammatory and hypoxic but not toxic liver damage in rodents. Inflammopharmacology 1991, 1:49-60.